




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 277/14, 417/04, 417/06, 417/12, 417/14, A61K 31/44	A1	(11) International Publication Number: WO 96/20936 (43) International Publication Date: 11 July 1996 (11.07.96)
(21) International Application Number: PCT/KR95/00183 (22) International Filing Date: 29 December 1995 (29.12.95) (30) Priority Data: 1994/38787 29 December 1994 (29.12.94) KR (71) Applicant (for all designated States except US): SUNKYONG INDUSTRIES CO., LTD. [KR/KR]; 600, Jungja-1 dong, Jangan-ku, Suwon-si, Kyungki-do 440-301 (KR). (72) Inventors; and (75) Inventors/Applicants (for US only): PARK, Pyeong-Uk [KR/KR]; Hyundai Apartment 20-603, Apgujong-dong, Kangnam-ku, Seoul 135-110 (KR). PYO, Sungsoo [KR/KR]; Jugong Apartment 702-402, Byulyang-dong, Gwacheon-si, Kyungki-do 427-040 (KR). LEE, Ki-Seung [KR/KR]; Dongsin Apartment 206-409, Jungja-1 dong, Jangan-ku, Suwon-si, Kyungki-do 440-301 (KR). GAM, Jongsik [KR/KR]; Jugong Apartment 254-101, 4, Wonmoon-dong, Gwacheon-si, Kyungki-do 427-030 (KR). SUNG, Jin, Heung [KR/KR]; Dosigyebal Apartment 901-106, Gayang-dong, Kangseo-ku, Seoul 157-200 (KR). PARK, Jung, Soo [KR/KR]; 40-14, Jungja-2 dong, Jangan-ku, Suwon-si, Kyungki-do 440-302 (KR). PARK, Don, Soo [KR/KR]; Samsung Apartment 7-206, Gwonsun-dong,		Gwonsun-ku, Suwon-si, Kyungki-do 441-390 (KR). RYU, Keun, Ho [KR/KR]; Jugong 2 Area Apartment 118-402, Maetan-dong, Suwon-si, Kyungki-do 442-370 (KR). PARK, Jeong, Ho [KR/KR]; 568-15, Pajang-dong, Jangan-ku, Suwon-si, Kyungki-do 440-290 (KR). (74) Agent: HUH, Sang, Hoon; Namyong Building, 5th floor, 809-16, Yeoksam-dong, Kangnam-ku, Seoul 135-707 (KR). (81) Designated States: AU, BR, CA, CN, HU, JP, NO, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>With amended claims.</i>

(54) Title: NOVEL THIAZOLIDIN-4-ONE DERIVATIVES**(57) Abstract**

The present invention relates to novel thiazolidin-4-one derivatives having formula (I), which inhibit platelet-activating factor and/or 5-lipoxygenase for the prevention or treatment of inflammatory and allergic disorders mediated by platelet-activating factor and/or leukotrienes, and to pharmaceutical compositions containing these compounds, and to the use thereof to inhibit PAF and/or leukotriene. A process for preparing these compounds is also included in the present invention, wherein n, T, Q, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are respectively as defined in the description.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam


NOVEL THIAZOLIDIN-4-ONE DERIVATIVES

BACKGROUND OF THE INVENTION

Field of the Invention

5 The present invention relates to novel thiazolidin-4-one derivatives having the following formula(I), which inhibit platelet-activating factor and/or 5-lipoxygenase for the prevention or treatment of inflammatory and allergic disorders mediated by platelet-activating factor and/or leukotrienes, and to pharmaceutical compositions containing these compounds, and to the use thereof to inhibit PAF and/or leukotriene.

10 A process for preparing these compounds is also included in the present invention.



wherein, n, T, Q, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are respectively defined as the below.

15

Description of the Related Art

Benveniste et al. found a factor in 1972 which strongly induces platelet aggregation from rabbit basophils. This factor was named platelet-activating factor (hereinafter referred to PAF). Hanahan et al. identified the factor in 1980 as a phosphoglyceride of the alkyl ether type having an acetyl group in the 2-position, i. e. 1-O-hexadecyl or octadecyl-2-acetyl-*sn*-glyceryl-3-phosphocholine.

20

The physiological roles of PAF have been intensively investigated, and it is known that PAF is an important factor acting on platelet aggregation, reduction in blood pressure, immediate allergic reaction, contraction of smooth muscle, inflammation, pain, edema, and alternation in the respiratory and circulatory systems.

25 Therefore, PAF-antagonistic activity-possessing compounds are very useful for

treating various PAF-induced diseases, such as inflammatory diseases, allergic diseases, anaphylactic shocks, septic shocks, vascular diseases as DIC, myocardial diseases, asthma, pulmonary edema, and adult respiratory diseases.

Leukotrienes, like PAF, are potent lipid mediators of a variety of topical and
5 systemic diseases and disorders. A 5-lipoxygenase in cytoplasm catalyzes the conversion of arachidonic acid to leukotriene A₄ which is the precursor of leukotriene B₄ and C₄. Leukotriene B₄ and C₄ are oxygenated metabolites that contribute to the pathogenesis of such inflammatory disorders as arthritis, asthma, psoriasis, and thrombotic disease. Leukotrienes are released concomitantly from leukocytes with
10 PAF from a common phospholipid precursor upon cellular activation and act synergistically with PAF in many biological models.

It has been demonstrated by O'Donnell and Lewis et al. that a physical combination of a PAF antagonist and leukotriene inhibitor is significantly more effective than either agent alone in treating asthma in an animal model [Therapeutic
15 Approaches to inflammatory Diseases, Lewis et al., Elsevier, New York, 1989, pp 169~193]. Shen et al. and Page et al. pointed out that single compounds which possess the dual inhibitory activity of PAF and leukotriene inhibition would have greater anti-inflammatory activities than a physical combination of a PAF and a leukotriene inhibitor. [PAF and Related Lipid Mediators, Plenum Pub., N.Y., 164
20 (1987) ; Trends in Pharmacol. Sci., 10(1989)].

Moreover, the chemical combination of PAF and 5-lipoxygenase inhibitory activities in one molecule has advantages over drug combinations in terms of optical pharmacokinetics, clinical applications and developmental costs.

Under these circumstances, various thiazolidin-4-one derivatives have been
25 synthesized. But thiazolidin-4-one compounds simultaneously possessing PAF-antagonistic activity and leukotriene inhibition activity have not been known at this time.

Reports related to thiazolidin-4-one derivatives are as followings: *N*-(phenyl,

pyridyl)-2-pyridyl-thiazolidin-4-one derivatives for agricultural chemicals [Japanese Patent Kokai No. 145679/79]; *N*-(phenyl, benzyl, cycloalkyl)-2-pyridyl-thiazolidin-4-one derivatives for agricultural chemicals [Japanese Patent Kokai No. 55184/80]; *N*-(carboxycyclohexylmethyl)-2-pyridyl-thiazolidin-4-one derivatives for
5 anticomplementary activity [Japanese Patent Application Kokai No. 85380/82]; *N*-(carboxymethylphenyl)-2-pyridyl-thiazolidin-4-one derivatives having anti-inflammatory and analgesic activity [Japanese Patent Kokai No. 88170/82]; *N*-(pyrazinyl)-2-pyridyl-thiazolidin-4-one derivatives for agricultural chemicals [Japanese Patent Kokai No. 183689/83]; *N*-(phenyl)-2-pyridyl-thiazolidin-4-one
10 derivatives for intermediates in synthesis [U.S. Patent No. 4,501,746]; *N*-(carbamoyloxy)-2-pyridyl-thiazolidin-4-one derivatives for cardiotonic [Japanese Patent Kokai No. 103883/86]; *N*-(alkyl, aminoalkyl)-2-pyridyl-thiazolidin-4-one derivatives for PAF-antagonist [Japanese Patent Kokai No. 126391/87, 139304/87, 160481/87, 12379/88 and European Patent Application No. 292305/88] etc..

15 Because of the large number of diseases and disorders which are mediated by PAF and leukotrienes, synthesis of new compounds which possess leukotriene or PAF inhibitory activity, and preferably compounds which possess both inhibitory activity will be very useful as active ingredients in the prevention and/or treatment of those diseases and disorders.


20 Accordingly, the present inventors have conducted long term investigations and studies on thiazolidin-4-one derivatives which have PAF antagonistic activity and/or leukotrienes inhibitory activity. The present invention has been accomplished based on these findings.

25 SUMMARY OF THE INVENTION

It is an object of this invention to provide novel thiazolidin-4-one derivatives which act as PAF antagonists and/or inhibit biosynthesis of leukotrienes via the 5-lipoxygenase pathway, the pharmaceutical uses of these derivatives, and a process for

preparing them.

The present invention relates to the novel thiazolidin-4-one derivatives having the following formula(I), which act as PAF antagonists and/or inhibit biosynthesis of leukotrienes via the 5-lipoxygenase pathway.



wherein, :

n is 0, 1, 2 or 3;

Q is $C_1 \sim C_{10}$ alkyl group, phenyl group that is optionally substituted with one or more suitable substituents selected from methoxy group and nitro group, or pyridyl group that is optionally substituted with one or more methyl group;


R^1 , R^2 and R^3 are independently hydrogen atom, $C_1 \sim C_{10}$ alkyl group, $C_3 \sim C_6$ cycloalkyl group, or phenyl group that is optionally substituted with one or more methoxy group;

R^4 , R^5 , R^6 , R^7 and R^8 are independently hydrogen atom, hydroxyl group, halogen atom, $C_1 \sim C_{10}$ alkyl group, $C_1 \sim C_{10}$ alkoxy group, nitro group, amino group that is optionally substituted with one or more suitable substituents selected from $C_1 \sim C_{10}$ alkyl group and $C_3 \sim C_6$ cycloalkyl group, phenyl group that is

optionally substituted with one or more suitable substituents selected from methoxy group and nitro group, $C_1 \sim C_{10}$ haloalkyl group, $\text{C}_6\text{H}_5(\text{CH}_2)_m\text{O}-$, $-\text{CO}_2\text{H}$, $\text{OCH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$, $-\text{OC}(=\text{O})\text{R}^{15}$, $-\text{OCO}(=\text{O})\text{R}^{15}$, $-\text{C}(=\text{O})\text{R}^{15}$, $-\text{C}(=\text{O})\text{NHR}^{15}$, $-\text{C}(=\text{O})\text{OR}^{15}$, $-\text{NHC}(=\text{O})\text{R}^{15}$, $-\text{CH}_2\text{NH}-\text{R}^{15}$, $-\text{N}(\text{OH})-\text{C}(=\text{O})\text{NHR}^{15}$, $-\text{C}(=\text{O})\text{N}(\text{OH})\text{R}^{15}$, $-\text{NHC}(=\text{O})\text{N}(\text{OH})\text{R}^{15}$, $-\text{CH}_2\text{NHC}(=\text{O})\text{N}(\text{OH})\text{R}^{15}$, $-\text{OC}(=\text{O})\text{NR}^{15}\text{R}^{15}$, $-\text{OC}(\text{R}^{16})_2-\text{C}(=\text{O})\text{OR}^{15}$, $-\text{OCH}_2-\text{O}-\text{C}(=\text{O})\text{R}^{15}$, $\text{O}-\text{C}(=\text{O})-(\text{CH}_2)_m-\text{C}(=\text{O})\text{OH}$, or $-\text{O}-\text{C}(=\text{O})-(\text{CH}_2)_m-\text{C}(=\text{O})\text{OR}^{15}$ (in which R^{15} is $C_1 \sim C_{10}$ alkyl group; m

is 1, 2, 3 or 4); and

T is hydrogen atom, hydroxyl group, $C_1 \sim C_{10}$ alkyl group,



- 5 or $-(CH_2)_m-NR^{13}R^{14}$ (in which, m is 1, 2, 3 or 4; R^9 is hydrogen atom, phenyl group that is optionally substituted with one or more suitable substituents selected from $C_1 \sim C_6$ alkyl group and $C_1 \sim C_6$ alkoxy group, or a pyridyl group; R^{10} is hydrogen atom, $C_1 \sim C_{10}$ alkyl group, or $C_1 \sim C_4$ alkanoyl group; R^{11} is $C_1 \sim C_{10}$ alkyl group, $C_1 \sim C_{10}$ alkoxy group, or amino group that is optionally substituted with one or more
- 10 suitable substituents selected from $C_1 \sim C_{10}$ alkyl group and $C_3 \sim C_6$ cycloalkyl group; R^{12} is $C_1 \sim C_{10}$ alkyl group or phenyl group; R^{13} is hydrogen atom, $C_1 \sim C_{10}$ alkyl group, or $C_1 \sim C_{10}$ alkanoyl group; R^{14} is hydrogen atom or $C_1 \sim C_{10}$ alkyl group or when taken together, connecting R^{13} and R^{14} , a substituted or unsubstituted four- to seven-membered cycloamino group, or a cycloamino group
- 15 having another hetero atoms; and R^{16} is hydrogen atom or $C_1 \sim C_{10}$ alkyl group.

The present invention also includes pharmaceutically acceptable salts of the formula(I), including, for example, salts with mineral acids such as, e.g., hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic acid such as, e.g., formic acid, acetic acid, malic acid, citric acid, maleinic

20 acid, fumalic acid or tartaric acid.

And the compounds according to the invention, as well as the pharmacuetically acceptable salts thereof, may be existed geometrical or optical isomerism. Thus the present invention includes isomer in each case the isomerism and hydrate of the compounds.

25

DETAILED DESCRIPTION OF THE INVENTION

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory, and are intended to


provide further explanation of the invention as claimed.

Novel compounds(I) of the present invention can be prepared by reacting compound of formula(II)



5 wherein, T and Q are defined as in the formula(I);


with compound of formula(III)



wherein, n, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are defined as in the formual(I);

in the presence of base and solvent at -78 °C to reflux temperature, via the

10 formula (I-1) as an intermidate



wherein, n, T, Q, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are defined as in formula(I).

The reaction of compound(II) with compound(III) is preferably carried out in a suitable solvent which at least one selected from inert organic solvents such as, e.g., tetrahydrofuran, benzene, toluene, dichloromethane or dichloroethane, and polar organic solvents such as, e.g., methanol, ethanol, dimethylsulfoxide, *N,N*-dimethylformamide or acetic acid. The basic medium for the reaction of compound (II) and (III) is preferably metal hydride such as, e.g., sodium hydride, potassium hydride or calcium hydride, lithium diisopropylamide, methyl lithium, butyl lithium, phenyl lithium, sodium methoxide, sodium ethoxide, sodium acetate, sodium


15

20

hydroxide, potassium hydroxide, or organic base such as, e.g., triethyl amine, piperidine or morpholine, etc..

Without isolation of the compound of formula(I-1) which is as an intermediate of the reaction mixtures, the reaction mixture can be reacted with an acid or alkali to

5 immediately obtain compound of the formula(I).




wherein, n, T, Q, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are defined as the above.

Suitable preferred acids are inorganic acid such as, e.g., hydrochloric acid, hydrochloric acid/methanol or hydrochloric acid/ethanol, or organic acid such as, e.g.,
 10 acetic acid or *p*-toluenesulfonic acid, etc.. And suitable preferred alkalis are sodium hydroxide, potassium hydroxide, sodium methoxide or sodium ethoxide, etc..


If the reaction of compound(II) with compound(III) is carried out at -78 °C to 0 °C, the formula(I-1) as intermediate may be isolated from the reaction mixture in a high yield.

15 Also, according to the present invention the compound of formula(I) can be prepared by reacting compound of formula(II-1)




wherein, T and Q are defined as in the formula(I), and X is halogen atom;

with compound of formula(III)



wherein, n , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are defined as in the formula(I);


in the presence of zinc and an organic solvent in which tetrahydrofuran, benzene, toluene or trimethoxyborane at $-78\text{ }^{\circ}\text{C}$ to reflux temperature, to obtain the formula (I-1) as intermediate



5


wherein, n , T , Q , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are defined as in the formula(I); and reacting the compound of formula(I-1) with the said acid or alkali.

Also, the present invention relates to process for preparing compound of formula(II-1)



10

wherein, T and Q are as defined in formula(I), and X is halogen atom; reacting compound of formula(II)



wherein, T and Q are defined as in formula(I);

15 with halide such as, e.g., bromine, iodine, chlorine, *N*-bromosuccinimide, *N*-bromophthalimide, *N*-chlorosuccinimide or *N*-chlorophthalimide in an organic solvents such as, e.g., ether, tetrahydrofuran, chloroform, carbon tetrachloride, dichloromethane, benzene, toluene, dimethyl formamide or etc. at $0\text{ }^{\circ}\text{C}$ to reflux temperature.

Also, the present invention relates to process for preparing compound of formula(II)



wherein, T and Q are defined as in formula(I);

- 5 by dehydrating the compound of Q-CHO(wherein, Q is defined as in the formula(I)) with compound of T-NH₂(wherein, T is defined in the formula(I)) and mercaptoacetic acid(HSCH₂CO₂H) in an organic solvent such as, e.g., benzene, toluene, xylene and etc..

It is to be understood that application of the teaching of the present invention to
 10 a specific problem or environment will be within the capabilities of one having ordinary skill in the art in light of the teachings contained herein. Examples of the products of the present invention and a representative process for their preparation and recovery appear in the following examples.

EXAMPLE 1.

- 15 Preparation of 3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one

< Method A >

A solution of 3-pyridinecarboxaldehyde(1.0 g, 9.15 mmol) and *N,N*-dimethylethylenediamine(0.822 g, 9.15 mmol) in toluene(30mL) was dehydrated under reflux for 1 h. The reaction mixture was allowed to cool to room temperature
 20 and evaporated to give 1.63 g(100 %) of *N*-nicotinylidene-*N',N'*-dimethylethylenediamine.

¹H NMR(300 MHz, CDCl₃) δ : 8.86(d, *J*=2.4Hz, 1H), 8.64(dd, *J*=4.8Hz, Δ*ν* = 15Hz), 8.35(s, 1H), 8.11(m, 1H), 7.33(m, 1H), 3.78(td, *J*=6.9, 1.2Hz, 2H), 2.68(t, *J*=6.9Hz, 2H), 2.34(s, 6H).

To a stirred solution of *N*-nicotinyldiene-*N',N'*-dimethylethylenediamine(1.63 g) in toluene(30mL) was added mercaptoacetic acid(0.64 mL, 9.15 mmol) and dehydrated at reflux for 1 h. The reaction mixture was allowed to cool to room temperature and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 2.14 g (93 %) of 3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one.

¹H NMR(300 MHz, CDCl₃) δ : 8.63(m, 1H), 8.56(d, *J*=2.1Hz, 1H), 7.68(m, 1H), 7.36(m, 1H), 5.93(s, 1H), 3.85~3.77(m, 3H), 2.74~2.69(m, 1H), 2.48~2.44(m, 1H), 2.29~2.21(m, 1H), 2.15(s, 6H).

< Method B >

A solution of 3-pyridinecarboxaldehyde(1.0 g, 9.15 mmol) and *N,N*-dimethylethylenediamine(0.822 g, 9.15 mmol) in toluene(30 mL) was dehydrated under reflux for 1 h. To reaction mixture was added mercaptoacetic acid(0.64 mL, 9.15 mmol) and dehydrated under reflux for 1 h. The reaction mixture was allowed to cool to room temperature and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 2.24 g(98 %)of 3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one.


< Method C >

A solution of 3-pyridinecarboxaldehyde(1.0 g, 9.15 mmol), *N,N*-dimethylethylenediamine(0.822 g, 9.15 mmol) and mercaptoacetic acid(0.64 mL, 9.15 mmol) in toluene(50 mL) was dehydrated under reflux for 2 h. The reaction mixture was allowed to cool to room temperature and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 2.22 g(97 %) of 3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one.

The intermediate compounds of formula(II) as shown in Table 1 were prepared in the same manner as described in EXAMPLE 1.











11











Table 1

















(II)




Example	T	Q	$^1\text{H NMR}(300 \text{ MHz, CDCl}_3) \delta$
			8.63(m, 1H), 8.56(d, J=2.1Hz, 1H), 7.68(m, 1H), 7.36(m, 1H), 5.93(s, 1H), 3.85~3.77(m, 3H), 2.74~ 2.69(m, 1H), 2.48~2.44(m, 1H), 2.29~2.21(m, 1H), 2.15(s, 6H)
5	1-1 		
10	1-2 		8.62(m, 1H), 8.55(m, 1H), 7.68(m, 1H), 7.38(m, 1H), 5.98(s, 1H), 3.65 ~3.85(m, 2H), 2.60~2.79(m, 2H), 2.33~2.57(m, 5H), 0.97(t, J=7.2Hz, 6H)
15	1-3 		8.62(m, 1H), 8.60(m, 1H), 7.66(m, 1H), 7.35(m, 1H), 5.94(s, 1H), 3.84(m, 1H), 3.78(m, 2H), 2.74(m, 2H), 2.41(m, 5H), 1.74(m, 4H)
20	1-4 		8.62(m, 1H), 8.55(m, 1H), 7.67(m, 1H), 7.35(m, 1H), 5.98(s, 1H), 3.72 ~3.88(m, 3H), 2.78(m, 1H), 2.51 (m, 1H), 2.29(m, 5H), 1.54(m, 4H), 1.42(m, 2H)













Example	T	Q	¹ H NMR(300 MHz, CDCl ₃) δ
5			8.63(m, 1H), 8.55(m, 1H), 7.68(m, 1H), 7.36(m, 1H), 5.89(s, 1H), 3.74~3.87(m, 3H), 3.67(m, 4H), 2.78(m, 1H), 2.48(m, 1H), 2.37(m, 5H)
10			8.63(m, 1H), 8.55(m, 1H), 7.68(m, 1H), 7.36(m, 1H), 5.92(s, 1H), 3.82(m, 1H), 3.78(m, 2H), 2.87(m, 4H), 2.77(m, 1H), 2.50(m, 1H), 2.35(m, 5H)
15			8.57(m, 1H), 8.52(m, 1H), 7.64(m, 1H), 7.10~7.44(m, 1H), 5.93(s, 1H), 4.21(s, 1H), 3.77(m, 3H), 2.73(m, 1H), 2.55(m, 1H), 2.39(m, 9H)
20			
25			8.63(m, 1H), 8.56(m, 1H), 7.67(m, 1H), 7.35(m, 1H), 5.71(s, 1H), 3.77(m, 2H), 3.68(m, 1H), 2.74(m, 1H), 2.24(m, 1H), 2.16(s, 6H), 1.70(m, 1H), 1.58(m, 1H)

Example	T	Q	¹ H NMR(300 MHz, CDCl ₃) δ
5	1-10 		8.61(m, 1H), 8.53(m, 1H), 8.46(m, 1H), 7.64(m, 2H), 7.34(m, 1H), 7.19(m, 2H), 5.54(s, 1H), 4.02(m, 1H), 3.70(m, 2H), 2.80~3.20(m, 3H)
10	1-11 		8.61(m, 1H), 8.41(m, 1H), 7.57(m, 1H), 7.33(m, 1H), 6.80(d, J=8.1Hz, 1H), 6.64 (m, 1H), 6.62(s, 1H), 5.25(s, 1H), 3.90 (m, 1H), 3.87(s, 3H), 3.85(s, 3H), 3.75 (m, 2H), 2.85(m, 2H), 2.68(m, 1H)
15	1-12 		8.63(m, 1H), 8.44(d, J=1.8Hz, 1H), 7.64 (m, 1H), 7.34(m, 1H), 6.70(d, J=7.8Hz, 1H), 6.62(s, 1H), 6.45(d, J=7.8Hz, 1H), 5.95(s, 2H), 5.42(s, 1H), 4.25(ABq, Δ ν =467, J _{AB} = 15.0Hz, 2H), 3.84(ABq, Δν =40.0, J _{AB} = 15.6Hz, 2H)
20	1-13 		8.60(m, 1H), 8.51(m, 1H), 7.60~ 7.76(m, 2H), 7.34(m, 1H), 7.19(m, 1H), 5.83(s, 1H), 5.04(d, J _{gem} = 15.3Hz, 1H), 3.90 (m, 2H), 3.81(d, J _{gem} =15.3Hz, 1H)
25	1-14 		





Example	T	Q	¹ H NMR(300 MHz, CDCl ₃) δ
5 1-15	CH ₃ CH ₂ CH ₂ -O-		
10 1-16	 -CH ₂ CH ₂ -		
15 1-17	H ₃ C-C(=O)-N(OH)-CH ₂ CH ₂ -		
20 1-18	H ₂ N-C(=O)-N(OH)-CH ₂ CH ₂ -		
25 1-19	H-N(OH)-C(=O)-CH ₂ -		8.63(m, 1H), 8.49(m, 1H), 7.34(m, 1H), 7.24(m, 1H), 5.89(s, 1H), 4.25(ABq, 2H), 3.98(ABq, 2H)
	1-20	 	8.61(m, 1H), 8.46(m, 1H), 8.22(m, 1H), 8.10(d, J=8.4Hz, 1H), 7.67(m, 2H), 7.25 (m, 1H), 7.01(m, 1H), 6.87(s, 1H), 3.95 (ABq, Δν = 56.7Hz, J _{AB} =16.2Hz, 2H)

Example	T	Q	¹ H NMR(300 MHz, CDCl ₃) δ
5	1-21		8.52(m, 1H), 8.40(m, 1H), 7.52(m, 1H), 7.51(s, 1H), 7.18(m, 1H), 5.45 (s, 1H), 4.62(m, 1H), 4.37(m, 1H), 3.87(m, 1H), 3.80(dd, 2H), 3.60(s, 3H), 3.40(m, 1H), 3.34(s, 3H)
10	1-22	OH	 8.57(s, 2H), 8.05(s, 1H), 7.78(d, J=7.8Hz, 1H), 7.33(m, 2H), 5.79(s, 1H), 3.66(s, 2H)
15	1-23	CH ₃ -(CH ₂) ₃ -	 8.64(m, 1H), 8.55(m, 1H), 7.68(m, 1H), 7.37(m, 1H), 5.65(d, J=1.5Hz, 1H), 3.70(m, 1H), 2.64(m, 1H), 1.44(m, 2H), 1.27(m, 2H), 0.87(t, J=7.5Hz, 3H)
20	1-24		
25	1-25	CH ₃ -	 4.78(dd, J=6.3, 1.8Hz, 1H), 3.82(td, J=7.2, 7.2Hz, 1H), 3.54(ABq, 2H), 3.07(td, J=7.2Hz, 2H), 2.35(m, 2H), 2.26(s, 6H), 1.92(m, 1H), 1.63(m, 1H), 1.18~1.46(m, 12H), 0.89(t, J=6.6Hz, 3H)
	1-26	 CH ₃ -(CH ₂) ₇ -	

Example	T	Q	¹ H NMR(300 MHz, CDCl ₃) δ
5			4.57(m, 1H), 3.56(dd, 2H), 2.90(s, 3H),
	1-27	CH ₃ — CH ₃ -(CH ₂) ₇ —	1.84~1.99(m, 1H), 1.57~1.80 (m, 1H),
			1.05~1.55(m, 12H), 0.89(t, J=6.6Hz, 3H)
10			4.58(m, 1H), 3.57(ABq, 2H), 2.89 (s,
	1-28	CH ₃ — CH ₃ -(CH ₂) ₅ —	3H), 1.90(m, 1H), 1.72(m, 1H), 1.32(m,
			8H), 0.89(t, J=6.6Hz, 3H)
15			4.58(m, 1H), 3.54(ABq, Δν =28, JAB=
	1-29	CH ₃ — CH ₃ -(CH ₂) ₂ —	15.6Hz, 2H), 2.90(s, 3H), 1.83~1.99(m,
			1H), 1.61~1.79(m, 1H), 1.32~1.52(m,
20			2H), 0.98(t, J=7.2Hz, 3H)
	1-30		
	1-31		6.52(s, 2H), 5.80(s, 1H), 3.86(s, 9H),
25			3.79(m, 1H), 3.77(m, 2H), 2.86(m, 1H),
	1-32		2.46(m, 1H), 2.34(m, 1H), 2.21(s, 6H)

Example	T	Q	¹ H NMR(300 MHz, CDCl ₃) δ
1-33			
1-34			
1-35			
1-36			8.61(m, 2H), 7.68(m, 1H), 7.37(m, 1H), 5.81(d, J=0.9Hz, 1H), 3.76(m, 3H), 3.68 (s, 3H), 3.06(m, 1H), 3.71(m, 1H), 2.46 (m, 1H)
1-37			8.63(m, 2H), 7.70(m, 1H), 7.38(m, 1H), 5.81(s, 1H), 3.78(m, 3H), 3.67(s, 3H), 3.05(m, 1H), 2.71(m, 1H), 2.46(m, 1H)
1-38			8.61(m, 1H), 8.57(m, 1H), 7.82(m, 1H), 7.45(m, 1H), 5.90(d, J=1.2Hz, 1H), 4.02 (q, J=7.2Hz, 2H), 3.92 (dd, J=15.6, 1.2Hz, 1H), 3.67(d, J=15.6Hz, 1H), 3.61~3.73 (m, 1H), 2.87(m, 1H), 2.54(m, 1H), 2.40(m, 1H), 1.15(t, J=7.2Hz, 3H)

Example	T	Q	¹ H NMR(300 MHz, CDCl ₃) δ	
1-39				
5	1-40			
	1-41			
10	1-42			
	1-43			
15	1-44			8.47(dd, J=4.8, 1.2Hz, 1H), 7.45 (dd, J=7.8, 1.5Hz, 1H), 7.21(m, 1H), 6.21(s, 1H), 3.85(td, J=7.8, 1.8Hz, 1H), 3.72(s, 2H), 2.72(m, 1H), 2.59(s, 3H), 2.52(m, 1H), 2.31(m, 1H), 2.13(s, 3H)
20	1-45			8.63(m, 1H), 8.56(d, J=2.1Hz, 1H), 7.68 (m, 1H), 7.36(m, 1H), 5.93(s, 1H), 3.85~3.77(m, 3H), 2.74~2.69 (m, 1H), 2.48~2.44(m, 1H), 2.15(s, 6H), 1.22(d, J=7.2Hz, 3H)
25	1-46			

Example	T	Q	¹ H NMR(300 MHz, CDCl ₃) δ
			DMSO-d ; 8.60(d, J=1.8Hz, 1H), 8.55
5	1-47		(dd, J=4.2, 1.8Hz, 1H), 7.85(m, 1H), 7.43(m, 1H), 5.85(s, 1H), 3.85 (ABq, Δ ν =72, J _{AB} =15.6Hz, 2H), 3.74(ABq, Δ ν =219, J _{AB} = 17.Hz, 2H)
10	1-48		8.53(m, 2H), 7.55(d, J=7.8Hz, 1H), 7.25 m, 1H), 4.79(m, 1H), 3.17 (ABq, 2H), 3.04(s, 3H)
15	1-49		8.47(m, 2H), 7.50(m, 1H), 7.23(m, 1H), 4.60(dd, J=1.8, 5.1Hz), 3.55 (m, 2H), 2.86(s, 3H), 2.68(t, J= 5.7Hz, 2H), 1.62~1.98(m, 4H)
20	1-50		12.34(brs, 1H), 8.60(m, 1H), 8.58 (m, 1H), 7.83(m, 1H), 7.45(m, 1H), 5.91(d, J=1.2Hz, 1H), 3.92 (dd, J=15.6, 1.2Hz, 1H), 3.67(d, J=15.6Hz, 1H), 3.63(m, 1H), 2.83(m, 1H), 2.54(m, 1H), 2.29(m, 1H)

Example	T	Q	¹ H NMR(300 MHz, CDCl ₃) δ
5			8.61(m, 1H), 8.56(m, 1H), 7.86(m, 1H), 7.42(m, 1H), 5.86(s, 1H), 4.14(d, J= 17.4Hz, 1H), 4.02(d, J= 15.6Hz, 1H), 3.01(q, J=7.2Hz, 2H), 3.74(d, J=15.6Hz, 1H), 3.58(d, J= 17.4Hz, 1H), 1.13(t, J= 7.2Hz, 3H)
1-51			
10			10.51(s, 1H), 8.80(s, 1H), 8.59(m, 2H), 7.82(m, 1H), 7.46(m, 1H), 5.88(s, 1H), 3.93(d, J=15.3Hz, 1H), 3.63(m, 1H), 3.67(d, J=15.3Hz, 1H), 2.80(m, 1H), 2.29(m, 1H), 2.07(m, 1H)
1-52			
15			

EXAMPLE 2.

Preparation of 3-(2-dimethylaminoethyl)-5-(α -hydroxybenzyl)-2-(3-pyridyl)-thiazolidin-4-one

< Method A >

5 To a solution of diisopropylamine (0.142 mL, 0.796 mmol) in tetrahydrofuran (10 mL) was added *n*-BuLi (1.6 M solution, 0.5 mL, 0.80 mmol) at -78 °C. After stirred for 1 h. To the reaction mixture was added 3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one (0.20 g, 0.796 mmol) dissolved in tetrahydrofuran (1.5 mL). After stirred for 30 min, to the reaction mixture was added benzaldehyde (98 μ L, 0.950 mmol) and stirred for 1 h and allowed to warm to room temperature. The reaction mixture was poured into brine (2 mL) and it was then extracted by using ethyl acetate (30 mL).

The ethyl acetate phase was dried over anhydrous magnesium sulfate and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 0.253 g (89 %) of 3-(2-dimethylaminoethyl)-5-(α -hydroxybenzyl)-2-(3-pyridyl)-thiazolidin-4-one.

$^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 8.62(m, 2H), 7.81(m, 1H), 7.36(m, 1H), 7.29~7.26(m, 5H), 5.84(s, 1H), 5.18(s, 1H), 4.52(s, 1H), 4.20(m, 1H), 2.75~2.35(m, 3H), 2.17(s, 6H).

20 **< Method B >**

To a solution of 3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one (0.35 g, 1.39 mmol) in carbon tetrachloride (30 mL) was added *N*-bromosuccinimide (0.260 g, 1.46 mmol) and benzoyl peroxide (1 mg). The reaction mixture was heated under reflux for 5 h in the dark and filtered off precipitate. The filtrate was evaporated to give crude 5-bromo-3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one.

$^1\text{H NMR}$ (300 MHz, CDCl_3) δ : 8.62~8.58(m, 2H), 7.70(d, $J=8.1\text{ Hz}$, 1H), 7.36~7.33(m, 1H), 5.94(s, 1H), 5.21(s, 1H), 4.68~4.80(m, 1H),

2.82(m, 1H), 2.61~2.43(m, 2H), 2.28(s, 6H).

To a solution of Zn(0.136 g, 2.09 mmol), CuBr(15 mg, 0.670 mmol) and diethylaluminium chloride (0.184 mg, 1.53 mmol) in mixture of tetrahydrofuran and hexane (10 mL/10 mL) was slowly added 5-bromo-3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one and benzaldehyde (0.162 g, 1.53 mmol) dissolved in tetrahydrofuran at -20 °C for 5 min. After stirred for 2 h, to the reaction mixture was added pyridine (1 mL) warmed to room temperature, diluted with water (10 mL) and extracted with ethyl acetate(80 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 0.468 g (94 %) of 3-(2-dimethylaminoethyl)-5-(α -hydroxybenzyl)-2-(3-pyridyl)-thiazolidin-4-one.

EXAMPLE 3.

Preparation of 3-(2-dimethylaminoethyl)-5-phenylmethylene-2-(3-pyridyl)-thiazolidin-4-one.

15 < Method A >

A solution of 3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one(0.130 g, 0.517 mmol) in tetrahydrofuran(10 mL) was cooled to 0 °C and added potassium hydride(51 mg, 1.29 mmol). After stirred for 5 min, to the reaction mixture was added benzaldehyde(64 μ l, 0.621 mmol) and warmed to room temperature. After stirred at room temperature for 1h, the reaction mixture was cooled to 0 °C, poured into water(0.2 mL), and extrated with ethyl acetate(20 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 0.166 g (95 %) of 3-(2-dimethylaminoethyl)-5-phenylmethylene-2-(3-pyridyl)-thiazolidin-4-one.

¹H NMR(300 MHz, CDCl₃) δ : 8.65~8.61(m, 2H), 7.66(d, J =8.1Hz, 1H), 7.53(s, 1H), 7.44~7.34(m, 5H), 6.18(s, 1H), 4.08~3.97(m, 1H), 2.78~2.82(m, 1H), 2.63~2.53(m, 1H),

2.40~2.35(m, 1H), 2.19(s, 6H).

< Method B >

To a solution of 3-(2-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one (0.126 g, 0.501 mmol) in acetic acid(10 mL) was added sodium acetate (0.165 g, 20.1 mmol) and benzaldehyde(80 mg, 0.751 mmol). The reaction mixture was heated under reflux for 8 h and evaporated to dryness. The residue was dissolved in water(5 mL) and extrated with ethyl acetate(30 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 0.144 g (85 %) of 3-(2-dimethylaminoethyl)-5-phenylmethylene-2-(3-pyridyl)-thiazolidin-4-one.

< Method C >

To a solution of 3-(2-dimethylaminoethyl)-5-(α -hydroxybenzyl)-2-(3-pyridyl)-thiazolidin-4-one(0.20 g) in toluene(10 mL) was added *p*-toluenesulfonic acid(10 mg). The reaction mixture was dehydrated under reflux for 2 h, cooled to room temperature, and evaporated. The residue was purified by flash column chromatography on silica gel to give 0.188 g (99 %) of 3-(2-dimethylaminoethyl)-5-phenylmethylene-2-(3-pyridyl)-thiazolidin-4-one.

< Method D >

A solution of 3-(2-dimethylaminoethyl)-5-(α -hydroxybenzyl)-2-(3-pyridyl)-thiazolidin-4-one(0.40 g) dissolved in 28 % HCl-ethanol (5 mL) was stirred for 10 min at room temperature and evaporated. The residue was purified by flash column chromatography on silica gel to give 0.345 g (91 %) of 3-(2-dimethylaminoethyl)-5-phenylmethylene-2-(3-pyridyl)-thiazolidin-4-one.

EXAMPLE 4.

Preparation of 3-(2-dimethylaminoethyl)-5-phenylmethylene-2-(3-pyridyl)-thiazolidin-4-one hydrochloride salt (Compound No. 1).

A solution of 3-(2-dimethylaminoethyl)-5-phenylmethylene-2-(3-pyridyl)-thiazolidin-4-one (0.50g) dissolved in 28 % HCl-ethanol (2 mL) was stirred for 3 h at room

temperature and filtered the precipitate. The precipitate was dried under vac. to give 0.537 g(97 %) of 3-(2-dimethylaminoethyl)-5-phenylmethylene-2-(3-pyridyl)-thiazolidin-4-one hydrochloride salt.

¹H NMR(300 MHz, DMSO-d₆) δ : 9.70(s, 1H), 8.79(s, 1H), 8.69(d, J=4.5Hz, 1H),
5 7.97(d, J=8.1Hz, 1H), 7.60~7.55(m, 6H), 6.39(s, 1H), 4.20~4.12(m, 1H), 3.21~3.00(m, 3H), 2.82(d, J=3.9Hz, 6H).

The compounds of formula(I), wherein R⁴, R⁵, R⁶, R⁷ or R⁸ is an hydroxyl group, can be prepared in the following EXAMPLE 5, introducing protecting group
10 such as methoxyethoxymethyl group.

EXAMPLE 5.

Preparation of 3-(2-N, N-dimethylaminoethyl)-5-(3,5-dimethyl-4-hydroxy-phenylmethylene)-2-(3-pyridyl)-thiazolidin-4-one hydrochloride salt (Compound No. 10)

15 A solution of 3,5-dimethyl-4-hydroxybenzaldehyde (10.0 g, 66.6 mmol) in tetrahydrofuran(100 mL) was cooled to 0 °C and added 80 % NaH (2.40 g, 79.9 mmol). After stirred for 10 min at 0 °C, to the reaction mixture was added 2-methoxyethoxymethyl chloride (11.6 g, 93.2 mmol) and warmed to room temperature. After stirred for 4 h, the reaction mixture was cooled to 0 °C and added methanol (10
20 mL). When no more evolution of hydrogen gas the reaction mixture was warmed to room temperature added water(20 mL) and extracted with ethyl acetate(2 x 100 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 13.6 g(86%) of 3,5-dimethyl-4-(2-methoxyethoxymethoxy)-benzaldehyde.
25

¹H NMR(300 MHz, CDCl₃) δ : 9.87(s, 1H), 7.55(s, 2H), 5.12(s, 2H), 3.95(t, J=4.5Hz, 2H), 3.60(t, J=4.5Hz, 2H), 3.39(s, 3H), 2.35(s, 6H)

To a solution of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one (1.00 g, 3.98 mmol) in tetrahydrofuran(50 mL) was added lithium diisopropylamide (1.5M solution, 3.18 mL) at -78 °C and stirred for 10 min. To the reaction mixture was slowly added 3,5-dimethyl-4-(2-methoxyethoxymethoxy)-benzaldehyde(1.13 g, 4.77 mmol) dissolved in tetrahydrofuran(5 mL). After stirred at -78 °C for 2 h, to the reaction mixture was added acetic acid(2 mL) and warmed to room temperature. The reaction mixture was neutralized with saturated sodium bicarbonate solution and extracted with ethyl acetate(3 x 30 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was dissolved in 30% HCl-ethanol solution(5 mL), stirred for 3 h and then neutralized with saturated sodium bicarbonate solution and extracted with ethyl acetate (2 x 50 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 1.32 g(87 %) of 3-(2-*N,N*-dimethylaminoethyl)-5-(3,5-dimethyl-4-hydroxy-phenylethylene)-2-(3-pyridyl)-thiazolidin-4-one.

¹H NMR(300 MHz, CDCl₃) δ : 8.63~8.61(m, 2H), 7.75(m, 1H), 7.54(s, 1H), 7.35(m, 1H), 7.21(s, 2H), 6.17(s, 1H), 4.15(m, 1H), 2.85(m, 1H), 2.60(m, 1H), 2.38(m, 1H), 2.18(s, 6H)

To a solution of 3-(2-*N,N*-dimethylaminoethyl)-5-(3,5-dimethyl-4-hydroxy-phenylethylene)-2-(3-pyridyl)-thiazolidin-4-one(1.32 g, 3.44 mmol) in ethanol(4 mL) was added 30 % HCl-ethanol solution(0.94 mL) and stirred at room temperature for 30 min. To the reaction mixture was added ethyl acetate(30 mL), filtered, and dried to give 1.49 g(95 %) of 3-(2-*N,N*-dimethylaminoethyl)-5-(3,5-dimethyl-4-hydroxy-phenylethylene)-2-(3-pyridyl)-thiazolidin-4-one hydrochloride salt.

¹H NMR(300 MHz, DMSO-d₆) δ : 9.60(brs, 1H), 8.80(s, 1H), 8.68(d, *J*=4.5Hz, 1H), 8.01(m, 1H), 7.61(m, 1H), 7.38(s, 1H), 7.16(s, 2H), 6.26(s, 1H), 4.20(m, 1H), 3.31~3.01(m, 3H), 2.82(d,

$J=3.8\text{Hz}$, 6H), 2.36(s, 6H)

The thiazolidin-4-one derivatives of formula(I) as shown in Table 2 were prepared in the same manner as described in EXAMPLE 1 to EXAMPLE 5.

5

10


15

20















25






















27






















Table 2










































5	Comp. No.	Q	T	R ¹	Ar	Salt
	1			H		HCl
10	2			H		
	3			H		
15	4			H		HCl
20	5			H		HCl
	6			H		HCl
25	7			H		


















Comp. No.	Q	T	R ¹	Ar	Salt
8		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	H		
9		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	H		HCl
10		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	H		HCl
11		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	H		
12		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	H		
13		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	H		
14		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	H		HCl






















	Comp. No.	Q	T	R ¹	Ar	Salt
5	15			H		HCl
	16			H		HCl
10	17			H		
15	18			H		HCl
	19			H		
20	20			H		HCl
25	21			H		HCl






















Comp. No.	Q	T	R ¹	Ar	Salt
5	22			H	 HCl
	23			H	 HCl
10	24			H	
15	25			H	
	26			H	
20	27			H	
25	28			H	






















Comp. No.	Q	T	R ¹	Ar	Salt
5	29			H	
	30			H	
	31			H	
10	32			H	
	33			H	
15	34			H	
	35			H	

Comp. No.	Q	T	R ¹	Ar	Salt
5			H		
					
10			H		
					HCl
15			H		
					
20			H		
					
25			H		















Comp. No.	Q	T	R ¹	Ar	Salt
5			H		
					
					
10			H		
					
					
15			H		
20			H		
25			H		

















Comp. No.	Q	T	R ¹	Ar	Salt
5			H		
10			H		
15			H		
20			H		
25			H		
			H		
			H		






















	Comp. No.	Q	T	R ¹	Ar	Salt
5	57			H		
	58			H		
10	59			H		
15	60			H		
	61			H		
20	62			H		
25	63			H		HCl















	Comp. No.	Q	T	R ¹	Ar	Salt
5	64			H		HCl
	65			H		
10	66			H		
	67			H		HCl
15	68			H		HCl
	69			H		HCl
20	70			H		HCl








Comp. No.	Q	T	R ¹	Ar	Salt
5	71		H		HCl
	72		H		
	73		H		HCl
10	74		H		
	75		H		
	76		H		
20	77		H		













Comp. No.	Q	T	R ¹	Ar	Salt
5	78		H		
	79		H		HCl
	80		H		HCl
15	81		H		
	82		H		
25	83		H		
	84		H		HCl










Comp. No.	Q	T	R ¹	Ar	Salt
5		CH ₃ CH ₂ CH ₂ -O—	H		HCl
			H		
			H		
10			H		
			H		HCl
			H		
20			H		HCl
			H		
			H		






















Comp. No.	Q	T	R ¹	Ar	Salt	
5	92			H		
	93			H		HCl
10	94			H		
	95			H		
15	96			H		
	97			H		
20	98			H		















	Comp. No.	Q	T	R ¹	Ar	Salt
5	99		OH	H		
	100		OH	H		HCl
10	101		OH	H		
15	102		OH	H		HCl
	103		OH	H		HCl
20	104		OH	H		HCl
25	105		OH	H		
















Comp. No.	Q	T	R ¹	Ar	Salt
5	106	OH	H		HCl
	107	OH	H		
	108	OH	H		HCl
	109	CH ₃ -(CH ₂) ₃ —	H		
	110	CH ₃ -(CH ₂) ₃ —	H		HCl
20	111	CH ₃ -(CH ₂) ₃ —	H		HCl
	112	CH ₃ -(CH ₂) ₃ —	H		

	Comp. No.	Q	T	R ¹	Ar	Salt
5	113		$\begin{array}{c} \text{H}_3\text{C} \\ \diagup \\ \text{CH}-\text{CH}_2\text{CH}_2- \\ \diagdown \\ \text{H}_3\text{C} \end{array}$	H		
	114		$\begin{array}{c} \text{H}_3\text{C} \\ \diagup \\ \text{CH}-\text{CH}_2\text{CH}_2- \\ \diagdown \\ \text{H}_3\text{C} \end{array}$	H		
10	115		CH ₃ -	H		
15	116		CH ₃ -	H		HCl
	117		CH ₃ -	H		HCl
20	118	CH ₃ -(CH ₂) ₇ -	$\begin{array}{c} \text{H}_3\text{C} \\ \diagup \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagdown \\ \text{H}_3\text{C} \end{array}$	H		
	119	CH ₃ -(CH ₂) ₇ -	$\begin{array}{c} \text{H}_3\text{C} \\ \diagup \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagdown \\ \text{H}_3\text{C} \end{array}$	H		
25						

	Comp. No.	Q	T	R ¹	Ar	Salt
5	120	CH ₃ -(CH ₂) ₇ —	CH ₃ -	H		
	121	CH ₃ -(CH ₂) ₇ —	CH ₃ -	H		
10	122	CH ₃ -(CH ₂) ₅ —	CH ₃ -	H		
	123	CH ₃ -(CH ₂) ₅ —	CH ₃ -	H		
15	124	CH ₃ -(CH ₂) ₂ —	CH ₃ -	H		
	125	CH ₃ -(CH ₂) ₂ —	CH ₃ -	H		
20	126			H		HCl

	Comp. No.	Q	T	R ¹	Ar	Salt
5	127			H		
	128			H		
10	129			H		
15	130			H		
	131			H		HCl
20	132			H		HCl
	133			H		HCl
25						

	Comp. No.	Q	T	R ¹	Ar	Salt
5	134		$\begin{matrix} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{matrix}$	H		
	135		$\begin{matrix} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{matrix}$	H		
	136		$\begin{matrix} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{matrix}$	H		
10	137		$\begin{matrix} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{matrix}$	H		
	138		$\text{CH}_3\text{OCH}_2\text{CH}_2-$	H		
15	139		$\text{CH}_3\text{CH}_2\text{OCH}_2\text{CH}_2-$	H		
	140		$\text{H}_3\text{C}-\text{C}(=\text{O})-\text{OCH}_2\text{CH}_2-$	H		
20						
25						

Comp. No.	Q	T	R ¹	Ar	Salt
5	141		$\text{CH}_3\text{CH}_2\text{O}-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2-$	H	
	142		$\text{C}_2\text{H}_5\text{O}-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2-$	H	
10	143		$\text{H}_3\text{C}-\text{C}(=\text{O})-\text{N}(\text{H})-\text{CH}_2\text{CH}_2-$	H	
15	144		 - $\text{C}(=\text{O})-\text{N}(\text{H})-\text{CH}_2\text{CH}_2-$	H	
	145		$\text{H}_3\text{C}-\text{N}(\text{CH}_3)-\text{C}(=\text{O})-\text{CH}_2\text{CH}_2-$	H	
20	146		 - $\text{C}(=\text{O})-\text{CH}_2\text{CH}_2-$	H	
25	147		 - $\text{C}(=\text{O})-\text{CH}_2\text{CH}_2-$	H	

EXAMPLE 6.

Preparation of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-5-(4-hydroxy-3-methoxyphenylallyliden)-thiazolidine-4-one hydrochloride salt(Compound No. 148)

A solution of 4-hydroxy-3-methoxy-cinnamaldehyde(2.0 g, 11.2 mmol) in
5 tetrahydrofuran(20 mL) was cooled to 0 °C and added 80 % NaH(0.404 g, 13.5 mmol).
After stirred for 10 min at 0 °C, to the reaction mixture was added 2-methoxyethoxymethyl chloride (1.68 g, 13.5 mmol) and warmed to room temperature.
After stirred for 3 h, the reaction mixture was cooled to 0 °C and added methanol(4 mL). When no more evolution of hydrogen gas the reaction mixture was warmed to
10 room temperature added water(10 mL), and extracted with ethyl acetate(2 x 50 mL).
The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 2.74 g(92 %) of 3-methoxy-4-(2-methoxyethoxymethoxy)-cinnamaldehyde.
15 ¹H NMR(300 MHz, CDCl₃) δ : 9.66(d, *J*=7.8Hz, 1H), 7.42(d, *J*=15.9Hz, 1H), 7.24
(d, *J*=8.4Hz, 1H), 7.13(dd, *J*=8.4, 2.1Hz, 1H), 7.09
(d, *J*=2.1Hz, 1H), 6.62(dd, *J*=15.9, 7.8Hz, 1H),
5.38(s, 2H), 3.89(s, 3H), 3.85(m, 2H), 3.55(m, 2H),
3.37(s, 3H)

20 To a solution of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one
(1.00g, 3.98 mmol) in tetrahydrofuran(30 mL) was added lithium diisopropylamide
(1.5M solution, 3.18 mL) at -78 °C and stirred for 10 min. To the reaction mixture
was slowly added 3-methoxy-4-(2-methoxyethoxymethoxy)-cinnamaldehyde(1.27 g,
4.77 mmol) dissolved in tetrahydrofuran(5 mL). After stirred at -78 °C for 3 h, the
25 reaction mixture was added acetic acid(4 mL) and allowed to warm to room
temperature. The reaction mixture was neutralized with saturated sodium
bicarbonate solution and extracted with ethyl acetate(2 x 50 mL). The combined
organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to

dryness. The residue was dissolved in 30% HCl-ethanol solution(10 mL) stirred at room temperature for 3h and then neutralized with saturated sodium bicarbonate solution, extracted with ethyl acetate(2 x 50 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to give pale yellow solids. The residue was purified by flash column chromatography on silica gel to give 1.35 g (83 %) of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-5-(4-hydroxy-3-methoxyphenylallylidene) thiazolidin-4-one.

¹H NMR(300 MHz, CDCl₃) δ : 8.62(m, 2H), 7.65(m, 1H), 7.38(m, 1H), 7.23(d, *J*=11.1Hz, 1H), 6.98(d, *J*=8.4Hz, 1H), 6.92(s, 1H), 6.85(d, *J*=8.4Hz, 1H), 6.75(d, *J*=15.3Hz, 1H), 6.58(dd, *J*=15.3, 11.1Hz, 1H), 6.15(s, 1H), 3.92(m, 1H), 3.91(s, 3H), 2.83(m, 1H), 2.59(m, 1H), 2.28(m, 1H), 2.20(s, 6H)

To a solution of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-5-(4-hydroxy-3-methoxyphenylallylidene)thiazolidin-4-one(1.35 g, 3.28 mmol) in ethanol(4 mL) was added 30 % HCl-ethanol solution(0.98 mL) and stirred at room temperature for 1 h. To the reaction mixture was added ethyl acetate(30 mL), filtered, and evaporated to give 1.53 g(97 %) of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-5-(4-hydroxy-3-methoxyphenylallylidene)-thiazolidine-4-one hydrochloride salt.

20 **EXAMPLE 7.**

Preparation of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-5-(3,5-dimethyl-4-hydroxyphenylallylidene)-thiazolidine-4-one (Compound No. 150)

A solution of 3,5-dimethyl-4-hydroxycinnamaldehyde(2.0 g, 11.4 mmol) in tetrahydrofuran(25 mL) was cooled to 0 °C and added 80 % NaH(0.425 g, 14.2 mmol). After stirred for 15 min at 0 °C, to the reaction mixture was added 2-methoxyethoxymethyl chloride(2.12 g, 17.0 mmol) and warmed to room temperature. After stirred for 4 h, the reaction mixture was cooled to 0 °C, added methanol(10 mL) and then warmed to room temperature, added water(20 mL), and extracted with ethyl

acetate(2 x 40 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 2.34 g(78 %) of 3,5-dimethyl-4-(2-methoxyethoxymethoxy)-cinnamaldehyde.

5 ^1H NMR(300 MHz, CDCl_3) δ : 9.65(d, $J=7.8\text{Hz}$, 1H), 7.36(d, $J=15.6\text{Hz}$, 1H), 7.24 (s, 2H), 6.02(dd, $J=15.6$, 7.8Hz, 1H), 5.09(s, 2H), 3.95(m, 2H), 3.62(m, 2H), 3.40(s, 3H), 2.31(s, 6H)

To a solution of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-thiazolidin-4-one (0.193g, 0.768 mmol) in tetrahydrofuran(8 mL) was added lithium diisopropylamide (1.5M solution, 1.0 mL) at -78 °C and stirred for 5 min. To the reaction mixture was slowly added 3,5-dimethyl-4-(2-methoxyethoxymethoxy)-cinnamaldehyde(0.225 g, 0.683 mmol) dissolved in tetrahydrofuran(1 mL). After stirred at -35 °C ~ -40 °C for 1 h, the reaction mixture was added acetic acid(1mL), allowed to warm to room temperature, and evaporated. To the residue was added 30 % HCl-ethanol solution(5 mL), stirred at room temperature for 2 h and it was then neutralized with saturated sodium bicarbonate solution and extracted with ethyl acetate(2 x 25 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 0.14 g (45 %) of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-5-(3,5-dimethyl-4-hydroxyphenylallylidene)-thiazolidine-4-one.

20 ^1H NMR(300 MHz, CDCl_3) δ : 8.64~8.59(m, 2H), 7.69~7.66(m, 1H), 7.37~7.33(m, 1H), 7.22(d, $J=11.1\text{Hz}$, 1H), 7.09(s, 2H), 6.72(d, $J=15.3\text{Hz}$, 1H), 6.55(dd, $J=15.3$, 11.1Hz, 3.98~3.90 (m, 1H), 2.86~2.77(m, 1H), 2.60~2.51(m, 1H), 2.37~2.28(m, 1H), 2.24(s, 6H), 2.18(s, 6H)

EXAMPLE 8.


Preparation of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-5-(3,5-dimethyl-4-ethoxycarbonyloxyphenylallylidene)-thiazolidine-4-one (Compound No. 175)

To a solution of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-5-(3,5-dimethyl-4-hydroxyphenylallylidene)-thiazolidine-4-one(0.537 g, 1.31 mmol) in pyridine(5 mL) was added ethyl chloroformate(0.284 g, 2.62 mmol), stirred at room temperature for 3 h, and evaporated. The residue was neutralized with saturated sodium bicarbonate solution and extracted with ethyl acetate(4 x 20 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered, and evaporated to dryness. The residue was purified by flash column chromatography on silica gel to give 1.35 g (83 %) of 3-(2-*N,N*-dimethylaminoethyl)-2-(3-pyridyl)-5-(3,5-dimethyl-4-ethoxycarbonyloxyphenylallylidene)-thiazolidine-4-one.

¹H NMR(300 MHz, CDCl₃) δ : 8.65~8.61(m, 2H), 7.68(m, 1H), 7.35(m, 1H), 7.21(d, *J*=11.1Hz, 1H), 7.10(s, 2H), 6.72(d, *J*=15.3Hz, 1H), 6.55(dd, *J*=15.3, 11.1Hz, 1H), 3.99(m, 1H), 3.53(q, *J*=7.6Hz, 2H), 2.83(m, 1H), 2.65(m, 1H), 2.30(m, 1H), 2.24(s, 6H), 2.19(s, 6H), 1.25(t, *J*=7.6Hz, 3H)

The thiazolidin-4-one derivatives of formula(I) as shown in Table 3, Table 4, and Table 5 were prepared in the same manner as described in EXAMPLE 6 to EXAMPLE 8 using the intermediates of formula(II).

Table 3



5





















10















15


















20






















25















Comp. No.	Q	T	R	Ar	Salt
148			H		
149			H		
150			H		
151			H		
152			H		
153			H		

Comp. No.	Q	T	R	Ar	Salt
5	154			H	
	155			H	
10	156			H	
	157			H	
15	158			H	
20	159			H	
	160			H	

	Comp. No.	Q	T	R	Ar	Salt
5	161		$\begin{matrix} \text{H}_3\text{C} \\ \text{H}_3\text{C} \end{matrix} \text{N-CH}_2\text{CH}_2\text{CH}_2\text{—}$	H		
	162		$\begin{matrix} \text{H}_3\text{C} \\ \text{H}_3\text{C} \end{matrix} \text{N-CH}_2\text{CH}_2\text{CH}_2\text{—}$	H		
10	163		 N-CH ₂ CH ₂ —	CH ₃ CH ₂ —		
15	164		$\begin{matrix} \text{H}_3\text{C} \\ \text{H}_3\text{C} \end{matrix} \text{N-CH}_2\text{CH}_2\text{—}$			
	165		 N-CH ₂ CH ₂ —	H		
20	166		$\begin{matrix} \text{C}_2\text{H}_5 \\ \text{C}_2\text{H}_5 \end{matrix} \text{N-CH}_2\text{CH}_2\text{—}$	H		
25	167		$\begin{matrix} \text{C}_2\text{H}_5 \\ \text{C}_2\text{H}_5 \end{matrix} \text{N-CH}_2\text{CH}_2\text{—}$	H		


Comp. No.	Q	T	R	Ar	Salt
5 168		$\begin{matrix} \text{H}_3\text{C} \\ \text{H}_3\text{C} \end{matrix} \text{N-CH}_2\text{CH}_2\text{—}$	$\text{CH}_3\text{CH}_2\text{—}$		
169		 N-CH ₂ CH ₂ —	H		
10 170		 N-CH ₂ CH ₂ —	H		
15 171		$\begin{matrix} \text{C}_2\text{H}_5 \\ \text{C}_2\text{H}_5 \end{matrix} \text{N-CH}_2\text{CH}_2\text{—}$	H		
172		$\begin{matrix} \text{C}_2\text{H}_5 \\ \text{C}_2\text{H}_5 \end{matrix} \text{N-CH}_2\text{CH}_2\text{—}$	H		
20 173		$\begin{matrix} \text{C}_2\text{H}_5 \\ \text{C}_2\text{H}_5 \end{matrix} \text{N-CH}_2\text{CH}_2\text{—}$	H		
174		$\begin{matrix} \text{H}_3\text{C} \\ \text{H}_3\text{C} \end{matrix} \text{N-CH}_2\text{CH}_2\text{—}$			

	Comp. No.	Q	T	R	Ar	Salt
5	175			H		
	176			H		
10	177			H		
	178			H		
15	179			H		
	180			H		
20	181			H		
25						
























Comp. No.	Q	T	R	Ar	Salt
182		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	H		
183		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	H		
184		CH ₃ -	H		
185		CH ₃ -	H		
186		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	CH ₃ CH ₂ CH ₂ -		
187		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	CH ₃ CH ₂ -		
188		CH ₃ -	H		

Comp. No.	Q	T	R	Ar	Salt
189			H		
190			H		
191			H		
192			H		
193			H		

Table 4



Comp. No.	Q	T	R	Ar	Salt
194		$\text{H}_3\text{C}-\text{N}(\text{CH}_3)_2-\text{CH}_2\text{CH}_2-$	CH_3-		
195		$\text{H}_3\text{C}-\text{N}(\text{CH}_3)_2-\text{CH}_2\text{CH}_2-$	CH_3CH_2-		
196		$\text{H}_3\text{C}-\text{N}(\text{CH}_3)_2-\text{CH}_2\text{CH}_2-$	$\text{CH}_3\text{CH}_2\text{CH}_2-$		
197		$\text{H}_3\text{C}-\text{N}(\text{CH}_3)_2-\text{CH}_2\text{CH}_2-$	CH_3-		
198		$\text{H}_3\text{C}-\text{N}(\text{CH}_3)_2-\text{CH}_2\text{CH}_2-$	CH_3-		
199		$\text{H}_3\text{C}-\text{N}(\text{CH}_3)_2-\text{CH}_2\text{CH}_2-$	CH_3CH_2-		

Comp. No.	Q	T	R	Ar	Salt
200					
201					
202					
203					
204					
205					
206					










Comp. No.	Q	T	R	Ar	Salt
207		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	$\text{CH}_3\text{CH}_2\text{CH}_2-$		
208		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	CH_3CH_2-		
209		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	CH_3-		
210		$\begin{array}{c} \text{H}_3\text{C} \\ \diagdown \\ \text{N}-\text{CH}_2\text{CH}_2- \\ \diagup \\ \text{H}_3\text{C} \end{array}$	CH_3-		

Table 5



Comp. No.	Q	T	Ar
211			
212			

Also NMR datas of the compounds of formula(I) according to the present invention were listed as shown in Table 6.

NMR solvent ; CDCl_3

DMSO-d_6 (Hydrochloride salts of formula(I))

Table 6

Comp. No.		¹ H NMR(300 MHz) δ
5	1	9.70(s, 1H), 8.79(s, 1H), 8.69(d, $J=4.5$ Hz, 1H), 7.97(d, $J=8.1$ Hz, 1H), 7.60~7.55(m, 6H), 6.39(s, 1H), 4.20~4.12(m, 1H), 3.21~3.00(m, 3H), 2.82(d, $J=3.9$ Hz, 6H)
	2	8.65(m, 2H), 7.70(m, 1H), 7.50(s, 1H), 7.38(m, 1H), 7.18(d, $J=8.4$ Hz, 1H), 7.05(s, 1H), 6.85(d, $J=8.4$ Hz, 1H), 6.18(s, 1H), 4.05(m, 1H), 3.90
	3	(s, 3H), 3.89(s, 3H), 2.82(m, 1H), 2.59(m, 1H), 2.38(m, 1H), 2.18(s, 6H)
	4	8.63(m, 2H), 7.66(m, 1H), 7.50(s, 1H), 7.36(m, 1H), 6.74(s, 2H), 6.18(s, 1H), 3.98(m, 1H), 3.87(s, 3H), 3.86(s, 3H), 3.85(s, 3H), 2.82(m, 1H), 2.69(m, 1H), 2.38(m, 1H), 2.18(s, 6H)
10	4	9.70(brs, 1H), 8.74(s, 1H), 8.64(m, 1H), 7.84(m, 1H), 7.80(m, 1H), 7.66
	6	(s, 1H), 7.58(m, 2H), 7.49(m, 1H), 6.38(s, 1H), 4.15(m, 1H), 3.38(m, 1H), 3.00~3.20(m, 2H), 2.82(s, 6H)
20	7	10.14(brs, 1H), 9.95(s, 1H), 8.79(d, $J=4.5$ Hz, 1H), 8.22(d, $J=8.1$ Hz, 1H), 7.78(dd, $J=8.1, 4.5$ Hz, 1H), 7.31(s, 1H), 6.97(s, 1H), 6.85(s, 2H), 6.46(s, 1H), 4.15(m, 1H), 3.65(m, 1H), 3.40(m, 1H), 3.15(m, 1H), 2.87
	8	(d, $J=3.6$ Hz, 6H)
25	7	8.62(m, 2H), 7.68(m, 1H), 7.50(s, 1H), 7.37(d, $J=9.0$ Hz, 2H), 7.35(m, 1H), 6.67(d, $J=9.0$ Hz, 2H), 6.11(s, 1H), 3.97(m, 1H), 3.38(q, $J=7.2$ Hz, 4H), 2.85(m, 1H), 2.55(m, 1H), 2.14(m, 1H), 2.18(s, 6H), 1.17(t, $J=7.2$ Hz, 6H)
	8	8.60(m, 2H), 7.95(s, 1H), 7.70(m, 2H), 7.54(m, 2H), 7.42(m, 1H), 7.38
		(m, 1H), 6.17(s, 1H), 4.10(m, 1H), 2.85(m, 1H), 2.60(m, 1H), 2.37(m, 1H), 2.18(s, 6H)

Comp. No.		¹ H NMR(300 MHz) δ
5	9	10.02(m, 2H), 8.88(brs, 1H), 8.77(brs, 1H), 8.13(m, 1H), 7.74(s, 2H),
		7.15(d, $J=8.7$ Hz, 1H), 6.45(s, 1H), 6.39(m, 1H), 6.32(m, 1H), 4.62(brs,
		1H), 4.12(m, 1H), 3.40(m, 1H), 3.15(m, 2H), 2.80(s, 6H)
10	10	9.87(brs, 1H), 8.86(d, $J=1$ Hz, 1H), 8.75(d, $J=4.5$ Hz, 1H), 8.17(d, $J=$
		7.6Hz 1H), 7.75(dd, $J=7.6, 4.5$ Hz, 1H), 7.34(s, 1H), 7.12(s, 2H), 6.39(s,
		1H), 4.05(m, 1H), 3.15(m, 3H), 2.81(s, 6H), 2.17(s, 6H)
15	11	8.61(m, 2H), 7.75(m, 1H), 7.54(s, 1H), 7.41(s, 2H), 7.38(m, 1H), 6.15(s,
		1H), 4.20(m, 1H), 2.85(m, 1H), 2.62(m, 1H), 2.38(m, 1H), 2.19(s, 6H),
		1.43(s, 18H)
20	12	8.62(m, 2H), 7.68(m, 1H), 7.54(s, 1H), 7.45(d, $J=9.0$ Hz, 2H), 7.27(m,
		1H), 6.94(d, $J=9.0$ Hz, 2H), 6.15(s, 1H), 3.98(m, 1H), 3.83(s, 3H), 2.85
		(m, 1H)
25	13	8.65(m, 1H), 8.61(m, 1H), 7.86(s, 1H), 7.66(m, 1H), 7.43~7.55(m, 2H),
		7.30(m, 1H), 7.26(m, 1H), 6.19(s, 1H), 4.01(m, 1H), 2.87(m, 1H), 2.59
		(m, 1H), 2.36(m, 1H), 2.19(s, 6H)
	14	9.79(brs, 1H), 8.82(s, 1H), 8.72(m, 1H), 8.03(m, 1H), 7.83(s, 1H), 7.65
		(m, 1H), 6.83(m, 2H), 6.72(m, 1H), 6.35(s, 1H), 4.14(m, 1H), 3.42(m,
		1H), 3.10(m, 2H), 2.82(m, 6H)
	15	9.72(brs, 1H), 9.43(brs, 1H), 8.80(brs, 1H), 8.70(brs, 1H), 7.98(m, 1H),
		7.75(s, 1H), 7.62(m, 1H), 6.82(m, 1H), 6.75(m, 1H), 6.62(m, 1H), 6.35(s,
		1H), 4.15(m, 1H), 3.40(m, 1H), 3.10(m, 2H), 2.82(m, 6H)
	16	9.50(brs, 1H), 9.00(brs, 1H), 8.72(m, 1H), 8.66(m, 1H), 7.88(m, 1H),
		7.78(s, 1H), 7.50(m, 1H), 6.72(d, $J=8.7$ Hz, 1H), 6.40(d, $J=8.7$ Hz, 1H),
		6.25(s, 1H), 4.12(m, 1H), 3.36(m, 1H), 3.08(m, 2H), 2.80(m, 6H)

Comp. No.	¹ H NMR(300 MHz) δ
5	17 8.65(m, 1H), 8.60(m, 1H), 7.66(m, 1H), 7.39~7.49(m, 5H), 7.20~7.39(m, 7H), 7.09(d, $J=1.8$ Hz, 1H), 7.03(m, 1H), 6.94(m, 1H), 6.12(s, 1H), 5.19(s, 2H), 5.17(s, 2H), 3.98(m, 1H), 2.84(m, 1H), 2.54(m, 1H), 2.33(m, 1H), 2.18(s, 6H)
	22 10.09(brs, 1H), 8.99(s, 1H), 8.82(d, $J=4.8$ Hz, 1H), 8.29(d, $J=8.1$ Hz, 1H), 7.83(dd, $J=7.8, 5.4$ Hz, 1H), 7.45(s, 1H), 7.38(t, $J=7.8$ Hz, 1H), 7.10(d, $J=7.8$ Hz, 1H), 7.06(s, 1H), 6.94(dd, $J=8.4, 1.8$ Hz, 1H), 6.52(s, 1H), 4.15(m, 1H), 3.82(s, 3H), 3.04~3.27(m, 2H), 2.81(s, 6H)
10	23 9.77(brs, 1H), 8.82(m, 1H), 8.74(m, 1H), 8.02(m, 1H), 7.64(m, 1H), 7.43(s, 1H), 6.82(s, 2H), 6.38(s, 1H), 4.15(m, 1H), 3.93(t, $J=6.3$ Hz, 4H), 3.86(t, $J=6.3$ Hz, 2H), 2.96~3.37(m, 3H), 2.81(s, 6H), 1.73(m, 4H), 1.65(m, 2H), 0.98(m, 9H)
	38 8.59(m, 2H), 7.62(m, 1H), 7.47(s, 1H), 7.32(m, 1H), 7.16(s, 2H), 6.21(s, 1H), 3.82(m, 1H), 2.85(m, 2H), 2.45(m, 5H), 2.29(s, 6H), 0.95(t, $J=6.9$ Hz, 6H)
20	39 10.1(brs, 1H), 8.93(s, 1H), 8.81(m, 1H), 8.24(m, 1H), 7.79(m, 1H), 7.31(s, 1H), 6.96(s, 1H), 6.83(m, 2H), 6.24(s, 1H), 4.04(m, 1H), 3.24(m, 2H), 3.13(m, 4H), 1.17(t, $J=7.2$ Hz, 6H)
	40 8.62(m, 2H), 7.68(m, 2H), 7.53(s, 1H), 7.35(m, 1H), 7.08(d, $J=8.2$ Hz, 1H), 7.05(s, 1H), 6.90(d, $J=8.2$ Hz, 1H), 6.19(s, 1H), 4.01(m, 1H), 3.90(s, 3H), 3.89(s, 3H), 2.80~3.02(m, 2H), 2.48(m, 5H), 1.77(m, 4H)

Comp. No.		¹ H NMR(300 MHz) δ
5	47	8.63(m, 2H), 7.67(m, 1H), 7.53(s, 1H), 7.35(m, 1H), 7.08(d, $J=8.4$ Hz, 1H), 7.05(s, 1H), 6.90(d, $J=8.4$ Hz, 1H), 6.21(s, 1H), 3.95(m, 1H), 3.90(s, 6H), 2.91(m, 1H), 2.82(m, 1H), 2.35(m, 5H), 1.57(m, 1H), 1.44(m, 2H)
	50	8.65(m, 1H), 8.61(m, 1H), 7.71(m, 1H), 7.53(s, 1H), 7.36(m, 1H), 7.09(d, $J=8.4$ Hz, 1H), 7.05(s, 1H), 6.91(d, $J=8.4$ Hz, 1H), 6.14(s, 1H), 3.96(m, 1H), 3.90(s, 3H), 3.89(s, 3H), 3.69(m, 4H), 2.93(m, 1H), 2.61(m, 1H), 2.43(m, 1H), 2.41(m, 4H)
10	67	8.81(s, 1H), 8.76(d, $J=4.8$ Hz, 1H), 8.08(d, $J=8.1$ Hz, 1H), 7.73(m, 1H), 7.16~7.29(m, 6H), 6.95(s, 1H), 6.83(s, 2H), 6.22(s, 1H), 3.92(m, 1H), 3.05(m, 1H), 2.95(m, 1H), 2.89(m, 1H)
	69	8.60(s, 1H), 8.59(s, 1H), 7.72(d, $J=7.8$ Hz, 1H), 7.45(m, 1H), 7.40(s, 1H), 6.99~7.27(m, 8H), 6.03(s, 1H), 3.95(m, 1H), 3.80(s, 3H), 3.79(s, 3H), 2.80~3.05(m, 2H), 2.60~2.80(m, 1H)
20	71	8.79(s, 1H), 8.75(d, $J=4.8$ Hz, 1H), 8.08(d, $J=8.1$ Hz, 1H), 7.72(m, 1H), 7.39(s, 1H), 7.27(s, 2H), 7.17(m, 5H), 6.20(s, 1H), 4.05(m, 1H), 3.05(m, 1H), 2.92(m, 1H), 2.85(m, 1H), 1.37(s, 18H)
	72	8.62(d, $J=5.1$ Hz, 1H), 8.39(s, 1H), 7.61~7.51(m, 2H), 7.40~7.30(m, 1H), 7.07(dd, $J=8.1, 2.1$ Hz, 1H), 7.03(d, $J=2.1$ Hz, 1H), 6.91(d, $J=8.1$ Hz, 1H), 6.83(d, $J=8.1$ Hz, 1H), 6.68(dd, $J=8.1, 1.5$ Hz, 1H), 6.64(d, $J=1.5$ Hz, 1H), 5.26(s, H), 4.10(m, 1H), 3.90(s, 3H), 3.89(s, 3H), 3.88(s, 3H), 3.82(s, 3H), 3.05~2.70(m, 3H)

Comp. No.		¹ H NMR(300 MHz) δ
5	74	8.76(m, 2H), 8.05(m, 1H), 7.71(m, 1H), 7.40(s, 1H), 7.11(s, 1H), 7.05(s, 1H), 6.83(d, $J=8.4$ Hz), 6.73(s, 1H), 6.65(d, $J=8.4$ Hz), 6.15(s, 1H), 4.05(m, 1H), 3.78(s, 3H), 3.76(s, 3H), 3.05(m, 1H), 2.80(m, 1H), 2.65(m, 1H), 2.17(s, 6H)
	78	8.65(d, $J=3.9$ Hz, 1H), 8.50(s, 1H), 7.70(d, $J=8.1$ Hz, 1H), 7.61(s, 1H), 7.40(m, 1H), 7.10(d, $J=6.9$ Hz, 1H), 7.04(s, 1H), 6.89(d, $J=8.1$ Hz, 1H), 6.70(d, $J=7.8$ Hz, 1H), 6.67(s, 1H), 6.52(d, $J=7.8$ Hz), 5.96(s, 2H), 5.61(s, 1H), 4.44(ABq, $\Delta\nu=477$, $J_{AB}=14.4$ Hz, 2H), 3.90(s, 3H), 3.89(s, 3H)
15	79	8.72(m, 2H), 8.06(d, $J=6.2$ Hz, 1H), 7.71(m, 1H), 7.36(s, 1H), 6.95(s, 1H), 6.79(m, 3H), 6.69(s, 1H), 6.58(d, $J=7.8$ Hz, 1H), 6.13(s, 1H), 5.97(s, 2H), 4.43(ABq, $\Delta\nu=228$, $J_{AB}=15.3$ Hz, 2H)
	80	8.78~8.76(m, 2H), 8.15(d, $J=8.1$ Hz), 7.77(dd, $J=8.1, 5.4$ Hz, 1H), 7.51(s, 1H), 7.30(s, 2H), 6.78(d, $J=8.1$ Hz, 1H), 6.70(s, 1H), 6.58(d, $J=8.1$ Hz, 1H), 6.17(s, 1H), 5.99(s, 2H), 4.45(ABq, $\Delta\nu=205.5$, $J_{AB}=15$ Hz, 2H), 1.38(s, 18H)
20	81	8.60(m, 2H), 8.52(m, 1H), 7.71(m, 1H), 7.66(m, 1H), 7.60(s, 1H), 7.46(d, $J=8.7$ Hz, 2H), 7.35(m, 1H), 7.22(m, 1H), 6.94(d, $J=8.7$ Hz, 2H), 6.04(s, 1H), 5.21(d, $J=15.3$ Hz, 1H), 4.04(d, $J=15.3$ Hz, 1H), 3.83(s, 3H)
	82	8.56~8.67(m, 2H), 8.52(m, 1H), 7.72(m, 1H), 7.65(m, 1H), 7.59(s, 1H), 7.34(m, 1H), 7.27(d, $J=6.6$ Hz, 1H), 7.20(m, 1H), 7.10(m, 1H), 7.06(m, 1H), 6.91(d, $J=6.6$ Hz, 1H), 6.04(s, 1H), 5.22(d, $J=15.3$ Hz, 1H), 4.03(d, $J=15.3$ Hz, 1H), 3.91(s, 3H), 3.90(s, 3H)
25		

Comp. No.	¹ H NMR(300 MHz) δ
5	83 8.62(m, 2H), 8.53(m, 2H), 7.73(m, 1H), 7.66(m, 1H), 7.56(s, 1H), 7.35(m, 1H), 7.21(m, 1H), 6.76(s, 2H), 6.07(s, 1H), 5.22(d, $J=15.3\text{Hz}$, 1H), 4.04(d, $J=15.3\text{Hz}$, 1H), 3.87(s, 9H)
	84 8.82(s, 1H), 8.73(m, 1H), 8.55(m, 1H), 8.20(m, 1H), 7.95(m, 1H), 7.74(m, 1H), 7.43(m, 2H), 7.35(s, 1H), 6.98(m, 1H), 6.85(m, 2H), 6.36(s, 1H), 5.01(d, $J=16.2\text{Hz}$, 1H), 4.36(d, $J=16.2\text{Hz}$, 1H)
10	85 8.70(m, 2H), 7.90(m, 1H), 7.58(m, 1H), 7.43(s, 1H), 6.85(s, 2H), 6.30(s, 1H), 3.42(m, 11H), 1.42(m, 2H), 0.98(t, $J=7.6\text{Hz}$, 3H)
15	86 8.62(m, 1H), 8.53(m, 1H), 8.49(m, 1H), 7.61(m, 2H), 7.50(s, 1H), 7.33(m, 1H), 7.19(m, 2H), 7.07(m, 1H), 7.02(m, 1H), 6.90(m, 1H), 5.65(s, 1H), 4.20(m, 1H), 3.90(s, 3H), 3.89(s, 3H), 3.31(m, 1H), 3.14(m, 1H), 3.06(m, 1H)
	87 8.61(m, 1H), 8.44~8.57(m, 2H), 7.60~7.74(m, 2H), 7.51(s, 1H), 7.18~7.37(m, 4H), 7.07(d, $J=7.5\text{Hz}$, 1H), 7.01(s, 1H), 6.90(m, 1H), 5.73(s, 1H), 4.21(m, 1H), 3.81(s, 3H), 3.30(m, 1H), 3.17(m, 2H)
	88 8.62(m, 1H), 8.53(m, 1H), 8.48(m, 1H), 7.56~7.70(m, 2H), 7.51(s, 1H), 7.43(d, $J=8.7\text{Hz}$, 2H), 7.29~7.37(m, 1H), 7.12~7.23(m, 2H), 6.93(d, $J=8.7\text{Hz}$, 2H), 5.63(s, 1H), 4.21(m, 1H), 3.82(s, 3H), 3.30(m, 1H), 3.15(m, 1H), 3.05(m, 1H)
20	89 8.72(m, 2H), 8.25(m, 1H), 7.93(m, 1H), 7.74(m, 2H), 7.60(m, 1H), 7.21(s, 1H), 7.07(s, 2H), 6.33(s, 1H), 4.12(m, 1H), 3.20(m, 3H), 2.16(s, 6H)

Comp. No.	¹ H NMR(300 MHz) δ
5	90 8.69(m, 2H), 8.37(s, 1H), 7.78(d, $J=7.8\text{Hz}$, 1H), 7.50(s, 1H), 7.41(m, 1H), 6.74(s, 2H), 5.99(s, 1H), 4.40(m, 1H), 4.13(m, 1H), 3.87(s, 9H), 3.17(d, $J=14.4\text{Hz}$, 1H), 3.05(d, $J=14.4\text{Hz}$, 1H), 2.04(s, 3H)
	91 9.90(brs, 1H), 8.89(s, 1H), 8.78(m, 1H), 8.20(d, $J=7.6\text{Hz}$, 1H), 7.79(m, 1H), 7.42(s, 1H), 7.08(m, 3H), 6.35(s, 1H), 3.89(m, 1H), 3.85(m, 1H), 3.78(s, 3H), 3.77(s, 3H), 3.61(m, 1H), 3.00(m, 1H), 1.94(s, 3H)
10	92 8.68(s, 2H), 8.42(s, 1H), 7.78(d, $J=7.6\text{Hz}$, 1H), 7.52(s, 1H), 7.41(m, 1H), 7.10(d, $J=8.4\text{Hz}$, 1H), 7.03(s, 1H), 6.90(d, $J=8.4\text{Hz}$, 1H), 6.00(s, 1H), 5.20(brs, 2H), 4.08(m, 2H), 3.91(s, 3H), 3.89(s, 3H), 3.14(m, 2H)
15	93 10.54(s, 1H), 8.83(s, 1H), 8.64(m, 1H), 7.77(d, $J=7.8\text{Hz}$, 1H), 7.48(m, 1H), 7.44(s, 1H), 6.88(s, 2H), 6.24(s, 1H), 3.86(m, 1H), 3.79(s, 6H), 3.69(s, 3H), 3.02(m, 1H), 2.38(m, 1H), 2.15(m, 1H)
	94 8.64(s, 1H), 8.49(d, $J=2.4\text{Hz}$, 1H), 7.74(d, $J=7.5\text{Hz}$, 1H), 7.42(s, 1H), 6.96(d, $J=8.4\text{Hz}$, 1H), 6.93(s, 1H), 6.78(d, $J=8.4\text{Hz}$, 1H), 6.12(s, 1H), 4.38(d, $J=15.9\text{Hz}$, 1H), 3.89(s, 3H), 3.84(s, 3H), 3.54(d, $J=15.9\text{Hz}$, 1H)
20	95 8.71(s, 1H), 8.50(m, 1H), 8.32(d, $J=8.4\text{Hz}$, 1H), 8.24(s, 1H), 7.72(m, 3H), 7.26(m, 1H), 7.09(m, 4H), 6.92(d, $J=8.4\text{Hz}$, 1H), 3.92(s, 6H)
	96 8.70(m, 1H), 8.47(m, 1H), 8.26(m, 2H), 7.69(m, 3H), 7.20(m, 1H), 7.07(s, 1H), 7.05(m, 1H), 6.79(s, 2H), 3.83(s, 3H), 3.82(s, 3H), 3.78(s, 3H)
25	97 8.72(m, 1H), 8.43(m, 1H), 8.24(m, 1H), 8.09(m), 7.67(m, 2H), 7.39(d, $J=8.4\text{Hz}$, 2H), 7.20(m, 1H), 7.07(s, 1H), 7.05(m, 1H), 6.71(d, $J=8.4\text{Hz}$, 2H), 6.49(s, 1H), 3.84(s, 3H)

Comp. No.		¹ H NMR(300 MHz) δ
5	98	8.53(m, 1H), 8.46(s, 1H), 7.52(m, 3H), 7.17(m, 1H), 7.07(d, $J=8.1$ Hz, 1H), 7.02(s, 1H), 6.91(d, $J=8.1$ Hz, 1H), 5.62(s, 1H), 4.79(m, 1H), 4.40(m, 1H), 4.15(m, 1H), 3.92(s, 3H), 3.90(s, 3H), 3.61(s, 3H),
	99	8.62(m, 2H), 8.05(s, 1H), 7.82(d, $J=7.8$ Hz, 1H), 7.49(s, 1H), 7.38(m, 1H), 7.03(s, 2H), 6.00(s, 1H), 3.90(s, 3H), 3.89(s, 3H), 3.88(s, 3H)
	100	9.56(s, 1H), 8.81(s, 1H), 8.71(m, 1H), 8.20(d, $J=8.1$ Hz, 1H), 7.74(m, 1H), 7.22(s, 1H), 7.08(s, 2H), 6.26(s, 1H), 2.17(s, 6H)
10	101	8.65(m, 2H), 8.06(s, 1H), 7.82(m, 1H), 7.50(s, 1H), 7.39(m, 1H), 7.09(d, $J=8.3$ Hz, 2H), 6.89(d, $J=8.3$ Hz, 2H), 6.01(s, 1H), 3.91(s, 3H)
	102	9.97(s, 1H), 8.83(s, 1H), 8.73(d, $J=5.1$ Hz, 1H), 8.20(d, $J=7.8$ Hz), 7.76(s, 1H), 7.74(m, 1H), 7.56(s, 3H), 6.36(s, 1H)
	103	9.56(s, 1H), 8.81(d, $J=1.5$ Hz, 1H), 8.72(d, $J=4.8$ Hz), 8.19(d, $J=8.1$ Hz, 1H), 7.75(m, 1H), 7.20(s, 1H), 6.93(s, 1H), 6.81(s, 2H), 6.26(s, 1H)
20	107	DMSO-d ₆ ; 9.56(s, 1H), 8.80(d, $J=1.5$ Hz, 1H), 8.71(d, $J=4.2$ Hz, 1H), 8.15(d, $J=8.1$ Hz, 1H), 7.73(dd, $J=7.8, 5.1$ Hz, 1H), 7.33(s, 1H), 7.27(s, 2H), 6.25(s, 1H), 4.8(brs, 1H), 1.38(s, 18H)
	109	8.65(m, 1H), 8.61(m, 1H), 7.68(m, 1H), 7.53(s, 1H), 7.36(m, 1H), 7.04(m, 2H), 6.90(m, 1H), 5.82(s, 1H), 4.13(q, $J=6.9$ Hz, 2H), 3.89(s, 3H), 3.88(m, 1H), 2.79(m, 1H), 1.52(m, 2H), 1.47(t, $J=6.9$ Hz, 3H), 1.28(m, 2H), 0.89(t, $J=7.5$ Hz, 3H)
	110	8.80(s, 1H), 8.72(m, 1H), 8.06(m, 1H), 7.66(m, 1H), 7.42(s, 1H), 7.01~7.17(m, 3H), 6.33(s, 1H), 3.78(s, 3H), 3.77(s, 3H), 3.68(m, 1H), 2.79(m, 1H), 1.42(m, 2H), 1.20(m, 2H), 0.83(t, $J=4.5$ Hz, 3H)

Comp. No.	¹ H NMR(300 MHz) δ
5	111 8.83(s, 1H), 8.74(s, 1H), 8.10(brs, 1H), 7.74(brs, 1H), 7.28(s, 1H), 6.95 (s, 1H), 6.81(m, 2H), 6.32(s, 1H), 4.25(brs, 2H), 3.75(m, 1H), 2.78(m, 1H), 1.43(m, 2H), 1.22(m, 2H), 0.85(t, $J=6.3\text{Hz}$, 3H)
10	112 8.63(m, 2H), 7.67(m, 1H), 7.53(s, 1H), 7.38(m, 1H), 7.05(d, $J=8.4\text{Hz}$, 1H), 7.04(s, 1H), 6.89(d, $J=8.4\text{Hz}$, 1H), 5.82(s, 1H), 4.00(t, $J=6.9\text{Hz}$, 2H), 3.92(m, 1H), 3.88(s, 3H), 2.80(m, 1H), 1.88(m, 2H), 1.52(m, 2H), 1.32(m, 2H), 1.01(t, $J=7.2\text{Hz}$, 3H), 0.89(t, $J=7.5\text{Hz}$, 3H)
15	115 8.66(d, $J=3.6\text{Hz}$, 1H), 8.62(d, $J=1.5\text{Hz}$, 1H), 7.68(d, $J=8.1\text{Hz}$, 1H), 7.54(s, 1H), 7.37(dd, $J=8.1, 3.6\text{Hz}$, 1H), 7.10(dd, $J=8.4, 1.8\text{Hz}$, 1H), 7.05(s, 1H), 6.91(d, $J=8.4\text{Hz}$, 1H), 5.72(s, 1H), 3.90(s, 6H), 2.91(s, 3H) 116 9.39(s, 1H), 9.18(s, 1H), 8.61~8.60(m, 2H), 7.74(d, $J=8.1\text{Hz}$, 1H), 7.47 (dd, $J=8.1, 4.8\text{Hz}$, 1H), 7.27(s, 1H), 6.97(d, $J=1.5\text{Hz}$), 6.85(dd, $J=8.4,$ 1.5Hz, 1H), 6.80(d, $J=8.4\text{Hz}$, 1H), 6.12(s, 1H), 3.34(s, 2H), 2.80(s, 3H)
20	117 8.92(d, $J=1.2\text{Hz}$, 1H), 8.44(d, $J=4.8\text{Hz}$, 1H), 8.28(d, $J=8.1\text{Hz}$, 1H), 7.89(dd, $J=8.1, 4.8\text{Hz}$, 1H), 7.49(s, 1H), 7.11(d, $J=1.8\text{Hz}$, 1H), 6.98(dd, $J=8.4, 1.8\text{Hz}$, 1H), 6.88(d, $J=8.4\text{Hz}$, 1H), 6.28(s, 1H), 5.40(brs, 3H), 3.78(s, 3H), 2.84(s, 3H) 118 7.26(s, 1H), 6.99(s, 1H), 6.87(d, $J=8.4\text{Hz}$, 1H), 6.78(d, $J=8.4\text{Hz}$, 1H), 4.96(d, $J=6.3\text{Hz}$, 1H), 4.1(brs, 2H, 2OH), 3.25(m, 1H), 2.66(m, 2H), 2.39(s, 6H), 1.87~2.05(m, 1H), 1.56~1.79(m, 1H), 1.31~1.50(m, 12H), 0.87(t, $J=6.6\text{Hz}$, 3H)

Comp. No.	¹ H NMR(300 MHz) δ
5	119 7.42(s, 1H), 7.14(d, $J=8.4$ Hz, 1H), 7.09(s, 1H), 6.92(d, $J=8.4$ Hz, 1H), 5.05(dd, $J=8.1, 2.1$ Hz, 1H), 3.98(m, 1H), 3.93(s, 3H), 3.91(s, 3H), 3.30 (m, 1H), 2.50(m, 1H), 2.29(s, 6H), 1.92(m, 1H), 1.74(m, 1H), 1.14~1.53 (m, 12H), 0.88(t, $J=6.3$ Hz, 3H)
10	120 7.36(s, 1H), 7.12(d, $J=1.8$ Hz, 1H), 6.98(d, $J=1.8$ Hz, 1H), 6.91(d, $J=$ 8.1Hz, 1H), 4.77(dd, $J=8.4, 1.8$ Hz, 1H), 3.06(s, 3H), 1.95~2.13(m, 1H), 1.65~1.82(m, 1H), 1.13~1.48(m, 12H), 0.88(t, $J=6.6$ Hz, 3H)
15	121 7.43(s, 1H), 7.14(dd, $J=8.4, 1.5$ Hz, 1H), 7.09(d, $J=1.5$ Hz, 1H), 6.92(d, $J=8.4$ Hz, 1H), 4.80(dd, $J=8.1, 1.8$ Hz, 1H), 3.93(s, 3H), 3.91(s, 3H), 3.07 (s, 3H), 1.97~2.13(m, 1H), 1.66~1.83(m, 1H), 1.15~1.52(m, 12H), 0.88 (t, $J=6.6$ Hz, 3H)
20	122 7.36(s, 1H), 7.12(d, $J=1.8$ Hz, 1H), 7.98(dd, $J=8.4, 1.8$ Hz, 1H), 6.91(d, $J=8.4$ Hz), 4.77(dd, $J=8.4, 2.7$ Hz, 1H), 3.06(s, 3H), 1.91~2.12(m, 1H), 1.63~1.81(m, 1H), 1.09~1.52(m, 8H), 0.88(t, $J=6.6$ Hz, 3H)
20	123 7.43(s, 1H), 7.14(dd, $J=8.4, 1.8$ Hz, 1H), 7.09(d, $J=1.8$ Hz, 1H), 6.94(d, $J=8.4$ Hz, 1H), 4.80(m, 1H), 3.93(s, 3H), 3.91(s, 3H), 3.07(s, 3H), 2.05 (m, 1H), 1.72(m, 1H), 1.30(m, 8H), 0.89(t, $J=6.6$ Hz, 3H)
25	124 8.03(brs, 2H), 7.33(s, 1H), 7.09(d, $J=1.8$ Hz, 1H), 6.96(dd, $J=8.4, 1.8$ Hz, 1H), 6.89(d, $J=8.4$ Hz, 1H), 4.79(dd, $J=8.1, 2.7$ Hz, 1H), 3.06(s, 3H), 1.95~2.12(m, 1H), 1.65~1.82(m, 1H), 1.32~1.55(m, 2H), 0.98(t, $J=$ 7.2Hz, 3H)

Comp. No.	¹ H NMR(300 MHz) δ
5	125 7.43(s, 1H), 7.14(dd, $J=8.4, 1.8\text{Hz}$, 1H), 7.09(d, $J=1.8\text{Hz}$, 1H), 6.92(d, $J=8.4\text{Hz}$, 1H), 4.80(dd, $J=8.1, 2.7\text{Hz}$, 1H), 3.93(s, 3H), 3.91(s, 3H), 3.07(s, 3H), 1.83~2.11(m, 1H), 1.64~1.84(m, 1H), 1.34~1.55(m, 2H), 0.99(t, $J=7.2\text{Hz}$, 3H)
	126 8.59(s, 1H), 8.02(brs, 1H), 7.31~7.52(m, 10H), 6.19(s, 1H), 4.63(ABq, $\Delta\nu = 224, J_{AB}=16.2\text{Hz}$, 2H), 1.38(s, 18H)
10	130 7.51(s, 1H), 7.12(d, $J=8.4\text{Hz}$, 1H), 7.06(s, 1H), 6.91(d, $J=8.4\text{Hz}$, 1H), 6.55(s, 2H), 6.01(s, 1H), 4.01(m, 1H), 3.90(s, 6H), 3.85(s, 9H), 3.00(m, 1H), 2.58(m, 1H), 2.47(m, 1H), 2.26(s, 6H)
	131 9.42(s, 1H), 9.21(s, 1H), 7.27(s, 1H), 6.97(s, 1H), 6.84(m, 2H), 6.76(s, 2H), 6.12(s, 1H), 4.12(m, 1H), 3.78(s, 6H), 3.67(s, 3H), 3.26(m, 3H), 2.81(s, 6H)
15	132 12.37(brs, 1H), 7.43(s, 1H), 7.16(s, 2H), 6.70(s, 2H), 6.10(s, 1H), 4.00(m, 1H), 3.87(s, 6H), 3.85(s, 3H), 3.68(m, 1H), 3.08~3.13(m, 2H), 2.87(d, $J=4.2\text{Hz}$, 3H), 2.79(d, $J=3.9\text{Hz}$, 3H), 2.26(s, 6H)
	133 10.0(s, 1H), 9.76(s, 1H), 9.41(brs, 1H), 7.71(s, 1H), 7.18(d, $J=8.7\text{Hz}$, 1H), 6.75(s, 2H), 6.40(s, 1H), 6.30(d, $J=8.7\text{Hz}$, 1H), 6.07(s, 1H), 4.05(m, 1H), 3.78(s, 6H), 2.25(s, 6H)
20	138 8.63(m, 2H), 7.69(d, $J=7.8\text{Hz}$, 1H), 7.54(s, 1H), 7.35(m, 1H), 7.03~7.16(m, 2H), 6.91(d, $J=8.4\text{Hz}$, 1H), 6.12(s, 1H), 4.03(m, 1H), 3.91(s, 3H), 3.90(s, 3H), 3.62(m, 1H), 3.52(m, 1H), 3.32(s, 3H), 2.94(m, 1H)

Comp. No.		¹ H NMR(300 MHz) δ
5	139	8.62(m, 2H), 7.69(d, $J=8.1$ Hz, 1H), 7.54(s, 1H), 7.35(m, 1H), 7.03~7.16(m, 2H), 6.91(d, $J=8.4$ Hz, 1H), 6.17(s, 1H), 4.05(m, 1H), 3.91(s, 3H), 3.90(s, 3H), 3.67(m, 1H), 3.40~3.58(m, 3H), 2.93(m, 1H), 1.92(t, $J=7.2$ Hz, 3H)
	140	8.65(m, 2H), 7.68(d, $J=8.1$ Hz, 1H), 7.54(s, 1H), 7.37(m, 1H), 7.09(d, $J=8.4$ Hz, 1H), 7.04(s, 1H), 6.90(d, $J=8.4$ Hz, 1H), 5.96(s, 1H), 4.30(m, 1H), 4.17(m, 2H), 3.91(s, 3H), 3.90(s, 3H), 3.05(m, 1H), 2.05(s, 3H)
10	141	8.66(brs, 2H), 7.69(m, 1H), 7.52(s, 1H), 7.36(m, 1H), 7.08(dd, $J=8.4$, 1.8Hz, 1H), 7.04(d, $J=1.8$ Hz, 1H), 6.90(d, $J=8.4$ Hz, 1H), 6.05(s, 1H), 4.14(q, $J=7.2$ Hz, 2H), 3.91(m, 1H), 3.90(s, 3H), 3.89(s, 3H), 3.19(m, 1H), 2.82(m, 1H), 2.50(m, 1H), 1.25(t, $J=7.2$ Hz, 3H)
	145	8.71(m, 1H), 8.61(m, 1H), 7.73(m, 1H), 7.50(s, 1H), 7.33(m, 1H), 7.09(d, $J=8.4$ Hz, 1H), 7.05(s, 1H), 6.90(d, $J=8.4$ Hz, 1H), 6.27(s, 1H), 3.90(s, 3H), 3.89(s, 3H), 3.78(m, 1H), 3.35(m, 1H), 3.00(m, 1H), 2.97(s, 3H), 2.94(s, 3H), 2.50(m, 1H)
20	146	DMSO-d ₆ ; 8.64(m, 1H), 8.60(m, 1H), 7.75(m, 1H), 7.44(m, 1H), 7.41(s, 1H), 7.12~7.05(m, 3H), 6.32(s, 1H), 3.78(s, 3H), 3.77(s, 3H), 3.30~3.21(m, 5H), 3.05(m, 1H), 2.67(m, 1H), 2.39(m, 1H), 1.77(m, 4H)
	148	8.62(m, 2H), 7.65(m, 1H), 7.38(m, 1H), 7.23(d, $J=11.1$ Hz, 1H), 6.98(d, $J=8.4$ Hz, 1H), 6.92(s, 1H), 6.85(d, $J=8.4$ Hz, 1H), 6.75(d, $J=15.3$ Hz, 1H), 6.58(dd, $J=15.3$, 11.1Hz, 1H), 6.15(s, 1H), 3.92(m, 1H), 3.91(s, 3H), 2.83(m, 1H), 2.59(m, 1H), 2.28(m, 1H), 2.20(s, 6H)

Comp. No.	¹ H NMR(300 MHz) δ
5	149 8.60(m, 2H), 7.70(d, $J=7.6$ Hz, 1H), 7.67(s, 1H), 7.39(dd, $J=7.6, 4.2$ Hz, 1H), 7.14(d, $J=11.1$ Hz, 1H), 6.97(s, 1H), 6.78(s, 2H), 6.70(d, $J=15.3$ Hz, 1H), 6.48(dd, $J=15.3, 11.1$ Hz, 1H), 6.17(s, 1H), 3.90(m, 1H), 2.80(m, 1H), 2.50(m, 1H), 2.35(m, 1H), 2.17(s, 6H)
10	150 8.64~8.59(m, 2H), 7.69~7.66(m, 1H), 7.37~7.33(m, 1H), 7.22(d, $J=11.1$ Hz, 1H), 7.09(s, 2H), 6.72(d, $J=15.3$ Hz, 1H), 6.55(dd, $J=15.3, 11.1$ Hz, 1H), 3.98~3.90(m, 1H), 2.86~2.77(m, 1H), 2.60~2.51(m, 1H), 2.37~2.28(m, 1H), 2.24(s, 6H), 2.18(s, 6H)
15	151 8.63(m, 2H), 7.67(m, 1H), 7.36(m, 1H), 7.23(d, $J=11.1$ Hz, 1H), 6.75(d, $J=15.6$ Hz, 1H), 6.68(s, 2H), 6.59(dd, $J=15.6, 11.2$ Hz, 1H), 6.16(s, 1H), 3.97(m, 1H), 3.91(s, 6H), 2.84(m, 1H), 2.55(m, 1H), 2.35(m, 1H), 2.18(s, 6H)
20	152 8.62(m, 2H), 7.69(m, 1H), 7.41(m, 1H), 7.23(s, 2H), 7.08(d, $J=11.2$ Hz, 1H), 6.91(d, $J=15.2$ Hz, 1H), 6.53(dd, $J=15.2, 11.2$ Hz, 1H), 6.24(s, 1H), 5.37(s, 1H), 3.94(m, 1H), 2.82(m, 1H), 2.57(m, 1H), 3.31(m, 2H), 2.31(m, 1H), 2.18(s, 6H), 1.21(d, $J=7.2$ Hz, 12H)
20	153 8.61(m, 2H), 7.69(dt, $J=7.8, 1.8$ Hz, 1H), 7.38(m, 1H), 7.25(s, 2H), 7.09(d, $J=11.1$ Hz, 1H), 6.92(d, $J=15$ Hz, 1H), 6.54(dd, $J=15.0, 11.1$ Hz, 1H), 6.25(s, 1H), 5.37(s, 1H), 3.92(m, 1H), 2.82(m, 1H), 2.56(m, 1H), 2.31(m, 1H), 2.18(s, 6H), 1.45(s, 18H)

Comp. No.	¹ H NMR(300 MHz) δ
5	158 8.62(m, 2H), 7.65(m, 1H), 7.38(m, 1H), 7.23(d, $J=11.1$ Hz, 1H), 7.11(m, 10H), 6.98(d, $J=8.4$ Hz, 1H), 6.92(s, 1H), 6.85(d, $J=8.4$ Hz, 1H), 6.75(d, $J=15.2$ Hz, 1H), 6.58(dd, $J=15.2, 11.1$ Hz, 1H), 6.25(s, 1H), 4.25(s, 1H), 3.92(m, 1H), 3.91(s, 3H), 2.83(m, 3H), 2.65(m, 8H)
10	159 8.62(m, 2H), 7.58(m, 1H), 7.42(m, 1H), 7.24(d, $J=11.2$ Hz, 1H), 6.97(d, $J=8.4$ Hz, 1H), 6.91(s, 1H), 6.82(d, $J=8.4$ Hz, 1H), 6.72(d, $J=15.3$ Hz, 1H), 6.55(dd, $J=15.3, 11.2$ Hz, 1H), 6.20(s, 1H), 3.95(m, 1H), 3.92(s, 3H), 2.83(m, 1H), 2.59(m, 6H), 1.82(m, 4H), 0.98(m, 2H)
15	160 8.64(m, 2H), 7.62(m, 1H), 7.40(m, 1H), 7.24(d, $J=11.1$ Hz, 1H), 6.98(d, $J=8.4$ Hz, 1H), 6.92(s, 1H), 6.85(d, $J=8.4$ Hz, 1H), 6.76(d, $J=15.3$ Hz, 1H), 6.57(dd, $J=15.3, 11.1$ Hz, 1H), 6.15(s, 1H), 3.95(m, 5H), 3.91(s, 3H), 3.62(m, 5H), 2.83(m, 1H), 2.59(m, 1H)
20	161 8.61(m, 2H), 7.68(m, 1H), 7.34(m, 1H), 7.22(d, $J=11.1$ Hz, 1H), 6.71(d, $J=15.6$ Hz, 1H), 6.68(s, 2H), 6.57(dd, $J=15.6, 11.1$ Hz, 1H), 5.93(s, 1H), 3.92(s, 6H), 3.82(m, 1H), 2.86(m, 1H), 2.20~2.40(m, 2H), 2.24(s, 6H), 1.50~1.90(m, 2H) 162 8.63(m, 2H), 7.69(m, 1H), 7.35(m, 1H), 7.23(d, $J=11.2$ Hz, 1H), 6.98(d, $J=8.2$ Hz, 1H), 6.93(s, 1H), 6.87(d, $J=8.2$ Hz, 1H), 6.73(d, $J=15.6$ Hz, 1H), 6.57(dd, $J=15.6, 11.2$ Hz, 1H), 5.90(s, 1H), 3.92(s, 3H), 3.79(m, 1H), 2.88(m, 1H), 2.26(m, 2H), 2.20(s, 6H), 1.55~1.95(m, 2H)

Comp. No.		¹ H NMR(300 MHz) δ
5	163	8.62(m, 2H), 7.65(m, 1H), 7.45(d, $J=12.0$ Hz, 1H), 7.33(m, 1H), 6.98(d, $J=8.4$ Hz, 1H), 6.85(d, $J=8.4$ Hz, 1H), 6.73(s, 1H), 6.18(d, $J=12$ Hz, 1H), 6.12(s, 1H), 4.15(m, 1H), 3.89(s, 3H), 2.79(m, 5H), 2.51(m, 4H), 1.74(m, 4H), 1.07(t, $J=7.6$ Hz, 3H)
	164	8.64(m, 2H), 7.75(m, 1H), 7.33(m, 1H), 7.25(m, 2H), 6.92(t, $J=8.4$ Hz, 1H), 6.82(m, 4H), 6.49(t, 1H), 6.12(s, 1H), 3.89(m, 1H), 3.79(s, 3H), 3.76(s, 3H), 2.82(m, 1H), 2.52(m, 1H), 2.31(m, 1H), 2.16(s, 6H)
10	165	8.63(m, 1H), 8.59(m, 1H), 7.66(m, 1H), 7.36(m, 1H), 7.23(d, $J=11.1$ Hz, 1H), 6.75(d, $J=15.3$ Hz, 1H), 6.67(s, 2H), 6.56(dd, $J=15.3, 11.1$ Hz, 1H), 6.17(s, 1H), 3.98(m, 1H), 3.91(s, 6H), 2.84(m, 2H), 2.45(m, 5H), 1.76(m, 4H)
15	166	8.64(m, 1H), 8.59(m, 1H), 7.66(m, 1H), 7.37(m, 1H), 7.22(d, $J=10.5$ Hz, 1H), 7.14(s, 2H), 6.60~6.80(m, 2H), 6.22(s, 1H), 4.32(q, $J=7.2$ Hz, 2H), 3.85(m, 1H), 2.68~2.92(m, 2H), 2.16~2.63(m, 5H), 2.20(s, 6H), 1.38(t, $J=7.2$ Hz, 3H), 0.99(t, $J=7.2$ Hz, 6H)
20	168	8.61(m, 2H), 7.66(m, 1H), 7.45(d, $J=12$ H, 1H), 7.34(m, 1H), 6.98(d, $J=8.4$ Hz, 1H), 6.89(d, $J=8.4$ Hz, 1H), 6.73(s, 1H), 6.19(d, $J=12$ Hz, 1H), 6.13(s, 1H), 3.90(s, 3H), 3.89(m, 1H), 2.76(m, 3H), 2.57(m, 1H), 2.21(m, 1H), 2.18(s, 6H), 1.22(t, $J=7.6$ Hz, 3H)
	169	8.63(m, 1H), 8.57(m, 1H), 7.64(m, 1H), 7.38(m, 1H), 7.19(d, $J=11.4$ Hz, 1H), 6.95(d, $J=8.4$ Hz, 1H), 6.91(s, 1H), 6.83(d, $J=8.4$ Hz, 1H), 6.73(d, $J=15.3$ Hz, 1H), 6.52(dd, $J=15.3, 11.4$ Hz, 1H), 6.15(s, 1H), 4.05(m, 1H), 3.90(s, 3H), 2.82(m, 2H), 2.45(m, 5H), 1.76(m, 4H)
25		

Comp. No.		¹ H NMR(300 MHz) δ
5	170	8.63(m, 1H), 8.60(m, 1H), 7.68(m, 1H), 7.37(m, 1H), 7.23(d, $J=11.1$ Hz, 1H), 7.08(s, 2H), 6.72(d, $J=15.3$ Hz, 1H), 6.56(dd, $J=15.3, 11.1$ Hz, 1H), 6.14(s, 1H), 3.96(m, 1H), 2.83(m, 2H), 2.44(m, 4H), 2.24(s, 6H), 1.75(m, 4H)
	171	8.63(m, 1H), 8.59(m, 1H), 7.66(m, 1H), 7.35(m, 1H), 7.22(d, $J=10.8$ Hz, 1H), 7.09(s, 2H), 6.72(d, $J=15.2$ Hz, 1H), 6.58(dd, $J=15.2, 10.8$ Hz, 1H), 6.20(s, 1H), 3.84(m, 1H), 2.68~2.92(m, 2H), 2.33~2.60(m, 6H), 2.24(s, 6H), 0.99(t, $J=7.2$ Hz, 6H)
10	173	8.64(m, 1H), 8.59(m, 1H), 7.66(m, 1H), 7.36(m, 1H), 7.21(d, $J=11.2$ Hz, 1H), 6.93(d, $J=8.2$ Hz, 1H), 6.93(s, 1H), 6.86(d, $J=8.2$ Hz, 1H), 6.75(d, $J=15.2$ Hz, 1H), 6.57(dd, $J=15.2, 11.2$ Hz, 1H), 6.22(s, 1H), 3.91(s, 3H), 3.85(m, 1H), 2.82(m, 2H), 2.52(m, 5H), 0.99(t, $J=7.2$ Hz, 6H)
	175	8.65~8.61(m, 2H), 7.68(m, 1H), 7.35(m, 1H), 7.21(d, $J=11.1$ Hz, 1H), 7.10(s, 2H), 6.72(d, $J=15.3$ Hz, 1H), 6.55(dd, $J=15.3, 11.1$ Hz, 1H), 3.99(m, 1H), 6.21(s, 1H), 4.32(q, $J=7.6$ Hz, 2H), 2.83(m, 1H), 2.65(m, 1H), 2.30(m, 1H), 2.24(s, 6H), 2.19(s, 6H), 1.25(t, $J=7.6$ Hz, 3H)
20	176	8.64(m, 1H), 8.61(m, 1H), 7.65(m, 1H), 7.36(m, 1H), 7.22(d, $J=10.5$ Hz, 1H), 7.14(s, 1H), 6.75(d, $J=14.3$ Hz, 1H), 6.64(dd, $J=14.3, 10.5$ Hz, 1H), 6.16(s, 1H), 4.32(q, $J=6.9$ Hz, 2H), 3.99(m, 1H), 2.83(m, 2H), 2.43(m, 5H), 2.19(s, 6H), 1.75(m, 4H), 1.38(t, $J=6.9$ Hz, 3H)

Comp. No.		¹ H NMR(300 MHz) δ
5	177	8.64~8.59(m, 2H), 7.70(m, 1H), 7.35(m, 1H), 7.23(d, $J=14.7$ Hz, 1H), 7.21(s, 1H), 7.14(s, 1H), 6.77(d, $J=16.5$ Hz, 1H), 6.51(dd, $J=16.5$, 14.7Hz, 1H), 6.13(s, 1H), 3.94(m, 1H), 2.82(m, 1H), 2.55(m, 1H), 2.33(m, 1H), 2.48(s, 3H), 2.18(s, 6H), 1.41(s, 9H)
	178	8.61(m, 2H), 7.67(m, 1H), 7.34(m, 1H), 7.27(d, $J=10.8$ Hz, 1H), 7.18(s, 1H), 7.10(d, $J=15$ Hz, 1H), 6.48(dd, $J=15$, 10.8Hz, 1H), 6.14(s, 1H), 3.95(m, 1H), 2.82(m, 1H), 2.58(m, 1H), 2.40(m, 1H), 2.26(s, 3H), 2.22(s, 3H), 2.21(s, 3H), 2.18(s, 6H)
	179	8.64(m, 1H), 8.58(m, 1H), 7.68(m, 1H), 7.36(m, 1H), 7.27(d, $J=11.2$ Hz, 1H), 6.89(d, $J=15.6$ Hz, 1H), 6.50(s, 1H), 6.17(dd, $J=15.6$, 11.2Hz, 1H), 6.12(s, 1H), 3.95(m, 1H), 2.80(m, 1H), 2.50(m, 1H), 2.30(m, 1H), 2.24(s, 3H), 2.28(s, 3H), 2.18(s, 6H), 2.15(s, 3H)
20	180	8.53~8.47(m, 2H), 7.64~7.73(m, 1H), 7.36(dd, $J=7.8$, 4.8Hz, 1H), 7.21(s, 1H), 7.02~7.12(m, 2H), 6.64~6.71(m, 1H), 6.63(s, 1H), 6.40(dd, $J=15.3$, 11.1Hz, 1H), 6.11(s, 1H), 3.96~4.08(m, 1H), 2.72~2.87(m, 1H), 2.49~2.60(m, 1H), 2.36~2.49(m, 1H), 2.25(s, 9H)
	181	8.65(m, 1H), 8.60(m, 1H), 7.68(m, 1H), 7.44(m, 2H), 7.22~7.41(m, 4H), 6.65~6.92(m, 2H), 6.16(s, 1H), 3.94(m, 1H), 2.82(m, 1H), 2.53(m, 1H), 2.32(m, 1H), 2.17(s, 6H)
	182	8.60~8.65(m, 2H), 7.67~7.69(m, 1H), 7.35~7.41(m, 1H), 7.24(d, $J=11.4$ Hz, 1H), 7.00(d, $J=8.1$ Hz), 6.82(d, $J=8.1$ Hz, 1H), 6.78(d, $J=15.1$ Hz), 6.59(dd, $J=15.1$, 11.4Hz, 1H), 6.15(s, 1H), 3.93(m, 1H), 3.91(s, 3H), 3.90(s, 3H), 2.84(m, 1H), 2.58(m, 1H), 2.33(m, 1H), 2.20(s, 6H)

Comp. No.	¹ H NMR(300 MHz) δ
5	183 9.10(brs, 1H), 8.62(m, 2H), 7.67(m, 1H), 7.38(m, 1H), 7.30(d, $J=8.4$ Hz, 2H), 7.19(d, $J=11.2$ Hz, 1H), 6.81(d, $J=8.4$ Hz, 2H), 6.76(d, $J=15.0$ Hz, 1H), 6.53(dd, $J=15.0, 11.2$ Hz, 1H), 6.15(s, 1H), 3.91(m, 1H), 2.83(m, 1H), 2.54(m, 1H), 2.32(m, 1H), 2.18(s, 6H)
10	184 8.65(dd, $J=4.8, 1.5$ Hz, 1H), 8.60(d, $J=2.1$ Hz, 1H), 7.68(td, $J=7.8, 1.8$ Hz, 1H), 7.40(m, 1H), 7.24(d, $J=11.4$ Hz, 1H), 7.01(dd, $J=8.1, 1.5$ Hz, 1H), 6.93(d, $J=1.5$ Hz, 1H), 6.88(d, $J=8.1$ Hz, 1H), 6.78(d, $J=15.3$ Hz, 1H), 6.55(dd, $J=15.3, 11.4$ Hz, 1H), 5.70(s, 1H), 3.92(s, 3H), 2.87(s, 3H)
15	185 8.55(m, 2H), 7.60(m, 1H), 7.29(m, 1H), 7.10(d, $J=11.4$ Hz, 1H), 6.97(m, 2H), 6.93(m, 1H), 6.87(d, $J=8.4$ Hz, 1H), 6.71(d, $J=15.3$ Hz, 1H), 6.51(dd, $J=15.3, 11.4$ Hz, 1H), 5.74(s, 1H), 4.96(dd, $J=9.0, 3.6$ Hz, 1H), 3.94(s, 3H), 3.46(dd, $J=13.5, 3.6$ Hz, 1H), 3.17(s, 3H), 2.90(dd, $J=13.5, 9.0$ Hz, 1H)
20	188 8.46(m, 2H), 7.51(m, 1H), 7.24(m, 1H), 7.14(d, $J=11.1$ Hz, 1H), 7.02(m, 1H), 6.95(s, 1H), 6.88(d, $J=8.1$ Hz, 1H), 6.73(d, $J=15.3$ Hz, 1H), 6.59(dd, $J=15.3, 11.1$ Hz, 1H), 5.81(s, 1H), 4.80(m, 1H), 3.94(s, 3H), 2.99(s, 3H), 2.69(m, 2H), 2.01(m, 1H), 1.82(m, 2H), 1.67(m, 1H)
	189 8.47(d, $J=3.3$ Hz, 1H), 7.46(d, $J=7.8$ Hz, 1H), 7.20(m, 2H), 7.07(s, 2H), 6.70(d, $J=15.3$ Hz, 1H), 6.50(dd, $J=15.3, 11.1$ Hz, 1H), 4.02(m, 1H), 2.80(m, 1H), 2.62(s, 3H), 2.59(m, 1H), 2.3(m, 1H), 2.34(s, 6H), 2.15(s, 6H)

Comp. No.	¹ H NMR(300 MHz) δ
5	190 8.47(m, 1H), 7.46(m, 1H), 7.20(m, 2H), 7.07(s, 2H), 6.68(d, $J=15.3$ Hz, 1H), 6.50(dd, $J=15.3, 11.1$ Hz, 1H), 4.31(q, $J=7.6$ Hz, 2H), 4.02(m, 1H), 2.80(m, 1H), 2.62(s, 3H), 2.59(m, 1H), 2.30(m, 1H), 2.34(s, 6H), 2.15(s, 6H), 1.25(t, $J=7.6$ Hz, 3H)
10	193 8.64(m, 1H), 8.60(m, 1H), 7.77(m, 1H), 7.35(m, 1H), 7.24(d, $J=11.1$ Hz, 1H), 7.08~7.00(m, 3H), 6.81(d, $J=15.3$ Hz, 1H), 6.67(dd, $J=15.3, 11.1$ Hz, 1H), 6.16(s, 1H), 4.31(q, $J=7.2$ Hz, 2H), 3.94(m, 1H), 3.87(s, 3H), 2.82(m, 1H), 2.56(m, 1H), 2.31(m, 1H), 2.17(s, 6H), 1.38(t, $J=7.2$ Hz, 3H)
15	194 8.63~8.58(m, 2H), 7.66(m, 1H), 7.35(m, 1H), 7.24(s, 1H), 6.96(s, 2H), 6.65(s, 1H), 6.07(s, 1H), 3.95(m, 1H), 2.83(m, 1H), 2.55(m, 1H), 2.30(m, 1H), 2.24(s, 6H), 2.17(s, 6H), 2.15(s, 3H)
195	8.63(m, 2H), 7.69(m, 1H), 7.34(m, 1H), 7.19(s, 1H), 6.95(s, 2H), 6.61(s, 1H), 6.08(s, 1H), 3.95(m, 1H), 2.85(m, 1H), 2.60~2.30(m, 2H), 2.95(m, 1H), 2.24(s, 6H), 2.17(s, 6H), 1.18(t, $J=7.6$ Hz, 3H)
20	196 8.63~8.58(m, 2H), 7.68(m, 1H), 7.35(m, 1H), 7.20(s, 1H), 6.93(s, 2H), 6.63(s, 1H), 6.07(s, 1H), 3.90(m, 1H), 2.85(m, 1H), 2.60~2.20(m, 4H), 2.24(s, 6H), 2.17(s, 6H), 1.69~1.22(m, 2H), 0.96(t, $J=8.7$ Hz, 3H)
25	197 8.57~8.67(m, 2H), 7.62~7.73(m, 1H), 7.31~7.40(m, 1H), 7.26(d, $J=2.7$ Hz, 1H), 6.82~6.96(m, 2H), 6.73(s, 1H), 6.08(s, 1H), 5.29(s, 1H), 3.90~4.05(m, 1H), 3.89(s, 3H), 3.88(s, 3H), 2.77~2.93(m, 1H), 2.48~2.64(m, 1H), 2.27~2.40(m, 1H), 2.19(s, 6H), 2.22(d, $J=0.9$ Hz, 3H)

Comp. No.	¹ H NMR(300 MHz) δ
5	198 8.58~8.64(m, 2H), 7.65~7.68(m, 1H), 7.34~7.37(m, 1H), 7.24(d, $J=7.5$ Hz, 1H), 6.80~6.87(m, 4H), 6.69(s, 1H), 6.07(s, 1H), 3.98~4.01 (m, 1H), 3.88(s, 3H), 2.77~2.92(m, 1H), 2.48~2.64(m, 1H), 2.27~2.39 (m, 1H), 0.21(s, 3H), 2.19(s, 6H)
10	199 8.59(m, 2H), 7.62(m, 1H), 7.38(m, 1H), 7.20(s, 1H), 6.87(m, 2H), 6.85(s, 1H), 6.09(s, 1H), 5.29(s, 1H), 3.88(s, 3H), 3.85(m, 1H), 2.85(m, 1H), 2.52(m, 3H), 2.25(m, 1H), 2.17(s, 6H), 1.27(t, $J=6.8$ Hz, 3H)
15	200 8.62(m, 2H), 7.64(m, 1H), 7.38(m, 1H), 7.19(s, 1H), 6.83(m, 3H), 6.66(s, 1H), 6.08(s, 1H), 3.98(m, 1H), 3.87(s, 3H), 2.85(m, 1H), 2.47(m, 4H), 2.19(s, 6H), 1.65(m, 2H), 0.94(t, $J=6.8$ Hz, 3H)
15	207 8.60(m, 2H), 7.68(m, 1H), 7.35(m, 1H), 7.20(s, 1H), 6.65(s, 1H), 6.55 (s, 2H), 6.10(s, 1H), 3.95(m, 1H), 3.87(s, 6H), 2.85(m, 1H), 2.30~2.60 (m, 4H), 2.18(s, 6H), 1.21(t, $J=7.6$ Hz, 3H)
20	208 8.62(m, 2H), 7.65(m, 1H), 7.38(m, 1H), 7.20(s, 1H), 6.65(s, 1H), 6.55(s, 2H), 6.10(s, 1H), 3.97(m, 1H), 3.88(s, 6H), 2.80(m, 1H), 2.54(m, 2H), 2.35(m, 2H), 2.19(s, 6H), 1.23(t, $J=7.6$ Hz, 3H)
20	211 8.63(d, $J=4.3$ Hz, 1H), 8.59(d, $J=1.8$ Hz, 1H), 7.62~7.73(m, 1H), 7.36 dd, $J=7.8, 4.8$ Hz, 1H), 7.13(d, $J=7.8$ Hz, 1H), 7.06(s, 2H), 6.59(m, 3H), 6.21 (dd, $J=13.8, 11.7$ Hz, 1H), 6.13(s, 1H), 3.98(m, 1H), 2.82(m, 1H), 2.59 (m, 1H), 2.38(m, 1H), 2.23(s, 6H), 2.17(s, 6H)

25 The present invention further relates to pharmaceutical compositions containing these compounds or acceptable salts thereof and the use of these compounds as antagonist of the PAF and/or inhibitor of the leukotriene. As stated above, compounds of the present invention possess activity of PAF-antagonist and/or

leukotriene-inhibition. Thus compounds of the invention may be used for the treatment and prophylaxis of diseases mediated or effected by PAF and leukotriene.

The typical diseases for which the compounds of the present invention may be used as a therapeutic and prophylactic agent include inflammation (for example, arthritis, nephritis), circulatory diseases (for example, shock, thrombosis, transplant rejection, cerebral anemia, etc.) and allergic diseases (for example, asthma, psoriasis).

The compounds according to the invention, as well as the pharmaceutically acceptable salts thereof, have potent PAF-antagonistic and leukotriene-inhibitory activity. Accordingly the novel compounds may be used in pharmaceutical composition comprising a pharmaceutically effective amount of one of the compounds defined above and a pharmaceutically acceptable carrier. The inventive compounds are particularly useful as anti-allergic agents, anti-asthmatic agents, anti-psoriasis agents, anti-anaphylactic shock agents, anti-septic shock agents, anti-arthritic agents, anti-nephritic agents, anti-thromboplastic agents, anti-transplant rejection agents and anti-cerebral anemic agents.

The compounds according to the present invention, as well as the pharmaceutically acceptable salt thereof, may be incorporated into convenient dosage forms such as capsules, tablets, or injectable preparations. Solid or liquid pharmaceutically acceptable carriers may also be employed. Solid carriers include starch, lactose, calcium sulphate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid. Liquid carriers include syrup, peanut oil, olive oil, saline solution and water.

The carrier or diluent may include any prolonged release material, such as glyceryl monostearate or glyceryl distearate, alone or with wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g. solution) or a nonaqueous or aqueous liquid suspension.

The pharmaceutical preparations are prepared conventional techniques of the

pharmaceutical chemist.

Compounds according to the present invention may be administered orally topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and
5 vehicles.

The term parenteral as used herein includes subcutaneous injections, intravenous injection, intramuscular injection, intrasternal injection or infusion techniques.

An exemplary daily dosage employed depends on the type of disease, the
10 degree of symptom and age. The dosage levels of the compound in the above-indicated compositions may, of course, be varied and may conveniently be between about 0.01mg to about 200 mg per kilogram of the weight.

Pharmaceutical compositions containing compounds according to the invention may be in any form suitable for oral use, for example, as tablets, troches, lozenges,
15 aqueous or oily suspensions, dispensable powders or granules, emulsion, hard or soft capsules, syrups or elixirs.

The tablets, capsules and the like may also contain a binder such as, e.g., lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin; excipients such as, e.g., dicalcium phosphate; a disintegrating agent such as, e.g., corn
20 starch or potato starch; a lubricant such as, e.g., magnesium stearate, calcium stearate, sodium stearylmalate or polyethylene glycol wax. When the dosage unit form is a capsule, it may further contain, in addition to the types of materials described above, a liquid carrier such as e.g., a fatty oil.

These active compounds according to the present invention may also be
25 administered parenterally. A solution or suspension of the active compounds may be prepared in water, optionally mixed with stabilizer or buffering agents. The dosages for parenteral administration are preferably as ampule or vial type.

These active compounds according to the invention may also be administered

by any known process of administrating the dose including topically, for example, an ointment, cream, jelly, solution, suspension or pachydematous patch; rectally, for example, suppository; intranasally or intrathoracally by inhalation spray.

Accordingly, the present invention provides pharmaceutical compositions comprising a pharmaceutically effective amount of thiazolidin-4-one derivatives and a pharmaceutically acceptable salt thereof. The present invention also provides the pharmaceutical uses of these compounds and compositions, especially for the prevent or treatment of various PAF- and/or leukotriene- induced diseases.

[pharmaceutical compositions]

10 Orally administration(Tablet) :

Composition	mg/Tablet	mg/Tablet
Active Ingredient	100	500
Lactose	122	113
Corn starch/water	30	40
15 Corn starch	45	40
Magnesium stearate	3	7
Total	300	700

Parenteral administration :

Composition	mg/vial	mg/vial
sterile active ingredient powder	100	500

※ Sterile water may be added to the above composition for intravenous injection.

25 The compounds of this invention were tested for pharmacological activity as described in the following pharmacology examples.

Pharmacology Example 1 : PAF-induced rabbit platelet aggregation.

Blood was collected from the ear artery of a male New Zealand white rabbit and mixed with 3.8 % sodium citrate in a 9:1 volume ratio. Platelet rich plasma (PRP) was obtained by centrifugation of blood at 150 g for 10 min at room temperature. The number of platelets was adjusted to 3×10^8 platelets/mL with platelet poor plasma. Platelet aggregation was monitored by continuous recording of light transmission in a dual-channel aggregometer (Chrono-Log 560-VS) coupled with a two channel recorder (Chrono-Log 707). Stirred PRP was treated with various concentration of test compounds or vehicle (0.5 % DMSO) for 2 min and then PAF (5×10^{-9} M) was added to induce platelet aggregation.

Inhibition values were calculated by comparing the extent of aggregation obtained in the presence of the vehicle alone (0.5 % DMSO) and in the presence of a test compound. Log concentration-response curves were generated and the IC_{50} values were determined by regression analysis.

Pharmacology Example 2 : Inhibitory activity for LTB_4 biosynthesis

A suspension of rat basophilic leukemia-1 cell in phosphoric acid buffer solution with a concentration of 5×10^6 /mL was allowed at 37°C for 5 min and added the compound of thiazolidin-4-one. After allowed for 5 min, to the mixture was added arachidonic acid ($25 \mu\text{L}/\text{mL}$) and calcium ionophore A23187 ($1 \mu\text{L}/\text{mL}$). After allowed for 15 min, the reaction mixture was quenched with 0.1N cooled hydrochloric acid and centrifuged with 3,300 rpm for 5 min. The supernatant solution was extracted with ethyl acetate and concentrated under nitrogen gas. The residue was dissolved in mobile phase and a amount of LTB_4 was determined with HPLC.

Table 7 lists result from this assay for inhibition of PAF-induced rabbit platelet aggregation and of LTB_4 biosynthesis for illustrative examples of the compounds of this invention.

Table 7 : Inhibitory activity of PAF-induced rabbit platelet aggregation and LTB₄ biosynthesis

5	Compound	PAF IC ₅₀	Inhibition of LTB ₄ biosynthesis
	No.	(μ M)	(%, 10 μ M)
10	1	1.741	30
	2	0.058	47
	3	0.079	54
	4	0.211	67
	6	1.901	85
15	7	0.065	74
	8	1.348	45
	9	15.21	63
	10	0.535	92
	11	0.496	89
20	12	0.141	42
	13	0.329	37
	14	4.21	75
	15	2.101	47
	16	3.21	25
25	17	0.721	43
	18	0.071	62
	19	0.046	65
	20	3.37	43
	21	1.021	89

	Compound No.	PAF IC ₅₀ (μ M)	Inhibition of LTB ₄ biosynthesis (%, 10 μ M)
5	22	0.274	41
	23	0.058	57
	38	2.123	92
	39	7.21	99
	40	0.501	42
10	63	0.258	39
	64	0.526	47
	67	3.21	100
	68	1.37	100
	69	1.21	65
15	70	4.74	75
	71	2.53	67
	72	4.21	17
	73	5.22	100
	74	4.72	100
20	78	3.73	45
	79	6.73	100
	80	7.21	65
	81	25.7	25
	82	4.21	30

	Compound	PAF IC ₅₀	Inhibition of LTB ₄ biosynthesis
	No.	(μ M)	(%, 10 μ M)
5	83	12.7	36
	84	25.8	100
	85	12.1	35
	86	15.7	40
	87	25.1	50
10	88	30.2	48
	89	22.7	100
	90	4.21	42
	91	13.72	65
	92	12.71	38
15	93	12.71	43
	94	27.2	17
	95	11.7	49
	96	10.5	37
	97	13.5	27
20	98	12.8	42
	99	12.5	52
	100	13.7	100
	101	14.2	42
	102	12.6	37

	Compound	PAF IC ₅₀	Inhibition of LTB ₄ biosynthesis
	No.	(μ M)	(%, 10 μ M)
5	103	13.8	100
	104	14.7	48
	105	12.7	47
	106	21.6	38
	107	9.76	63
10	108	12.1	63
	109	13.6	57
	110	12.7	37
	111	12.4	100
	112	11.3	67
15	115	12.5	28
	116	13.7	98
	117	13.4	42
	118	15.4	98
	119	9.78	45
20	120	7.21	100
	121	8.47	72
	122	8.52	100
	123	27.2	52
	124	25.7	100

	Compound	PAF IC ₅₀	Inhibition of LTB ₄ biosynthesis
	No.	(μ M)	(%, 10 μ M)
5	125	23.2	60
	126	21.8	95
	127	23.7	100
	128	20.5	47
	129	18.7	62
10	130	12.5	20
	131	14.2	95
	132	12.7	72
	133	13.5	25
	138	15.8	32
15	139	14.8	27
	140	15.6	42
	148	0.046	82
	149	1.21	93
	150	0.023	100
20	151	2.32	85
	152	0.125	52
	153	0.577	42
	158	4.21	100
	159	6.38	92

	Compound	PAF IC ₅₀	Inhibition of LTB ₄ biosynthesis
	No.	(μ M)	(%, 10 μ M)
5	161	9.82	60
	162	3.71	59
	163	0.087	40
	164	0.227	45
	165	4.82	75
10	169	0.115	63
	170	0.025	100
	171	0.050	100
	173	1.25	65
	175	0.018	100
15	176	0.020	100
	178	0.059	50
	179	0.194	10
	182	0.155	30
	184	7.8	100
20	185	8.2	100
	189	0.012	100
	190	0.010	100
	191	0.015	100
	193	0.042	80

	Compound	PAF IC ₅₀	Inhibition of LTB ₄ biosynthesis
	No.	(μ M)	(%, 10 μ M)
5	194	0.010	100
	195	0.042	80
	198	0.116	54
	201	0.012	100
	204	0.010	100
10	205	0.005	100
	209	0.002	100
	211	0.132	100
	212	1.25	100

15


20

25

WHAT IS CLAIMED IS :

1. A compound of the following formula(I) or a pharmaceutically acceptable salt thereof

5



wherein,

n is 0, 1, 2 or 3;

10 Q is $C_1 \sim C_{10}$ alkyl group, phenyl group that is optionally substituted with one or more suitable substituents selected from methoxy group and nitro group, or pyridiyl group that is optionally substituted with one or more methyl group;

15 R^1 , R^2 and R^3 are independently hydrogen atom, $C_1 \sim C_{10}$ alkyl group, $C_3 \sim C_6$ cycloalkyl group or phenyl group that is optionally substituted with one or more methoxy group;

20 R^4 , R^5 , R^6 , R^7 and R^8 are independently hydrogen atom, hydroxyl group, halogen atom, $C_1 \sim C_{10}$ alkyl group, $C_1 \sim C_{10}$ alkoxy group, nitro group, amino group that is optionally substituted with one or more suitable substituents selected from $C_1 \sim C_{10}$ alkyl group and $C_3 \sim C_6$ cycloalkyl group, phenyl group that is optionally substituted with one or more suitable substituents selected from methoxy group and nitro group, $C_1 \sim C_{10}$ haloalkyl group, $\text{C}_6\text{H}_5-(\text{CH}_2)_m-\text{O}-$,

5


$$\begin{aligned} & -\text{CO}_2\text{H}, \text{OCH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3, -\overset{\text{O}}{\parallel}\text{C}-\text{R}^{15}, -\overset{\text{O}}{\parallel}\text{C}-\text{O}-\text{R}^{15}, -\overset{\text{O}}{\parallel}\text{C}-\text{R}^{15}, -\overset{\text{O}}{\parallel}\text{C}-\text{NHR}^{15}, \\ & -\overset{\text{O}}{\parallel}\text{C}-\text{OR}^{15}, -\text{NHC}-\overset{\text{O}}{\parallel}\text{R}^{15}, -\text{CH}_2\text{NH}-\overset{\text{O}}{\parallel}\text{R}^{15}, -\text{N}(\text{OH})-\overset{\text{O}}{\parallel}\text{C}-\text{NHR}^{15}, -\overset{\text{O}}{\parallel}\text{C}-\text{N}(\text{OH})\text{R}^{15}, \\ & -\text{NHC}-\overset{\text{O}}{\parallel}\text{N}(\text{OH})\text{R}^{15}, -\text{CH}_2\text{NHC}-\overset{\text{O}}{\parallel}\text{N}(\text{OH})-\text{R}^{15}, -\text{OC}-\overset{\text{O}}{\parallel}\text{NR}^{15}\text{R}^{15}, -\text{OC}(\text{R}^{16})_2-\overset{\text{O}}{\parallel}\text{C}-\text{OR}^{15}, \\ & -\text{OCH}_2-\text{O}-\overset{\text{O}}{\parallel}\text{C}-\text{R}^{15}, \text{O}-\overset{\text{O}}{\parallel}\text{C}-(\text{CH}_2)_m-\overset{\text{O}}{\parallel}\text{C}-\text{OH}, \text{or } -\text{O}-\overset{\text{O}}{\parallel}\text{C}-(\text{CH}_2)_m-\overset{\text{O}}{\parallel}\text{C}-\text{OR}^{15} \text{ (in which R}^{15} \text{ is} \\ & \text{C}_1 \sim \text{C}_{10} \text{ alkyl group; and m is 1, 2, 3 or 4); and} \end{aligned}$$

T is hydrogen atom, hydroxyl group, C₁ ~ C₁₀ alkyl group,

10

$$\begin{aligned} & -(\text{CH}_2)_m-\text{R}^9, -(\text{CH}_2)_m-\text{O}-\text{R}^{10}, -(\text{CH}_2)_m-\overset{\text{O}}{\parallel}\text{C}-\text{R}^{11}, \\ & -(\text{CH}_2)_m-\text{NHC}-\overset{\text{O}}{\parallel}\text{R}^{12}, -(\text{CH}_2)_m-\text{N}(\text{OH})-\overset{\text{O}}{\parallel}\text{C}-\text{R}^{16}, -(\text{CH}_2)_m-\text{N}(\text{OH})-\overset{\text{O}}{\parallel}\text{CNH}_2, \\ & -(\text{CH}_2)_m-\overset{\text{O}}{\parallel}\text{CN}(\text{OH})-\text{R}^{16}, \text{ or } -(\text{CH}_2)_m-\text{NR}^{13}\text{R}^{14} \text{ (in which, m is 1, 2, 3} \\ & \text{or 4; R}^9 \text{ is hydrogen atom, phenyl group that is optionally substituted} \\ & \text{with one or more suitable substituents selected from C}_1 \sim \text{C}_6 \text{ alkyl group and} \\ & \text{C}_1 \sim \text{C}_6 \text{ alkoxy group, or a pyridyl group; R}^{10} \text{ is hydrogen atom, C}_1 \sim \text{C}_{10} \\ & \text{alkyl group or C}_1 \sim \text{C}_4 \text{ alkanoyl group; R}^{11} \text{ is C}_1 \sim \text{C}_{10} \text{ alkyl group, C}_1 \sim \text{C}_{10} \\ & \text{alkoxy group, or amino group that is optionally substituted with one or more} \\ & \text{suitable substituents selected from C}_1 \sim \text{C}_{10} \text{ alkyl group and C}_3 \sim \text{C}_6 \\ & \text{cycloalkyl group; R}^{12} \text{ is C}_1 \sim \text{C}_{10} \text{ alkyl group or phenyl group; R}^{13} \text{ is} \\ & \text{hydrogen atom, C}_1 \sim \text{C}_{10} \text{ alkyl group, or C}_1 \sim \text{C}_{10} \text{ alkanoyl group; R}^{14} \text{ is} \\ & \text{hydrogen atom or C}_1 \sim \text{C}_{10} \text{ alkyl group or when taken together, connecting} \\ & \text{R}^{13} \text{ and R}^{14}, \text{ a substituted or unsubstituted four- to seven-membered} \\ & \text{cycloamino group, or a cycloamino group having another hetero atoms; and} \\ & \text{R}^{16} \text{ is hydrogen atom or C}_1 \sim \text{C}_{10} \text{ alkyl group.} \end{aligned}$$

25 2. A pharmaceutical composition including a compound of the following formula (I) or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier



wherein, n, Q, T, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are respectively as defined in claim 1.


5

3. A process for treating PAF- and/or leukotriene-induced diseases which comprises the step of administering an effect amount of compound of formula (I) as claimed in claim 1 or pharmaceutically acceptable salt thereof, to a host in need of such treatment.

10

4. The process for treating PAF- and/or leukotriene-induced diseases as claimed in claim 3, the said diseases are arthritis, nephritis, anaphylactic shock, septic shock, thrombosis, transplant rejection, cerebral anemia, asthma or psoriasis.

5. A process for preparing compound of the following formula(I) or acceptable salt thereof



wherein, n, T, Q, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are respectively as defined in claim 1; reacting compound of the following formula(II)


20

97



wherein, T and Q are as in defined 1;

with compound of the following formula(III)




5


wherein, n, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are respectively as defined in claim 1.

6. A process for preparing compound of the following formula(I) or pharmaceutically acceptable salt thereof

10




wherein, n, T, Q, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are respectively as defined in claim 1; reacting compound of the following formula(II-1)




15

wherein, T and Q are as defined in claim 1, and X is halogen atom;
with compound of the following formula(III)



5 wherein, n, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are respectively as defined in claim 1;

to obtain compound of the following formula (I-1)




10 wherein, n, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are respectively as defined in claim 1; and


reacting the compound of the above formual(I-1) with an acid or alkali.

7. A process for preparing a compound having the following formual(II-1) by

15




wherein, T and Q are as defined in claim 1, and X is halogen atom;
reacting compound of the following formula(II)



wherein, T and Q are as defined in claim 1;
with halides.


- 5 8. A process for preparing compound of the following formula(II) by



wherein, T and Q are defined as defined in claim 1;
dehydrating compound of Q-CHO (wherein, Q is as defined in claim 1) with
10 compound of T-NH₂ (wherein, T is as defined in claim 1) and mercaptoacetic
acid (HSCH₂CO₂H).

AMENDED CLAIMS

[received by the International Bureau on 3 May 1996 (03.05.96);
original claim 6 cancelled;
remaining claims unchanged (1 page)].



(II)

wherein, T and Q are as defined in claim 1;
with halides.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 95/00183

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 07 D 277/14, 417/04, 417/06, 417/12, 417/14; A 61 K 31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 07 D 277/00, 417/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AT, Chemical Abstracts

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Questel - DARC, CAS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 292 305 A1 (SUMITOMO) 23 November 1988 (23.11.88), example 63; page 2, lines 6-50; claim 1.	1-4
A	Chemical Abstracts, Vol.112, No.7, 12 February 1990 (Columbus, Ohio, USA), page 772, column 2, abstract No.55851q, ENOMOTO, M. et al.: "Optically active thiazolidin-4-ones as platelet activating factor (PAF) antagonists", Jpn. Kokai Tokkyo Koho JP 01,190,679.	1-4
A	Chemical Abstracts, Vol.96, No.21, 24 May 1982 (Columbus, Ohio, USA), page 704, column 1, abstract No.181185q, DASH, B. et al.: "Thiazolidone derivatives", J. Indian Chem. Soc. 1981, 58(12), 1184-6 (Eng).	1
A	Chemical Abstracts, Vol.76, No.11, 13 March 1972 (Columbus, Ohio, USA), page 460, column 2, abstract No.59509v, SNIDER, R.H. et al.: "Friedel-Crafts reaction with 5-arylidene-4-thiazolidinones", Int. J. Sulfur Chem., Part A 1971, 1(3), 191-6 (Eng).	1

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

01 March 1996 (01.03.96)

Date of mailing of the international search report

15 March 1996 (15.03.96)

Name and mailing address of the ISA/AT

AUSTRIAN PATENT OFFICE

Kohlmarkt 8-10

A-1014 Vienna

Facsimile No. 1/53424/535

Authorized officer

Hammer

Telephone No. 1/5337058/44

INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 95/00183

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Chemical Abstracts, Vol.92, No.13, 31 March 1980 (Columbus, Ohio, USA), page 653, column 2, abstract No.110910d, PANDYA, U.H. et al.: "Studies on thiazolidinones. Part VII", J. Inst. Chem. (India) 1979, 51(3), 129-30 (Eng).	8
Y	Chemical Abstracts, Vol.114, No.23, 10 June 1991 (Columbus, Ohio, USA), page 870, column 2, abstract No.229205r, DUNN, A.D. et al.: "Sulfur analogs of deoxyvasicinone. Part 5. Synthesis of methylated analogs", Z. Chem. 1990, 30(8), 288-9 (Eng).	8
Y	Chemical Abstracts, Vol.113, No.11, 10 September 1990 (Columbus, Ohio, USA), page 411, column 2, abstract No.94650p, PISCOPO, E. et al.: "Studies on heterocyclic compounds: 1,3-thiazolidin-4-one derivatives. IV. Biological activity of variously substituted 2,3-diaryl-1,3-thiazolidin-4-ones", Boll.-Soc. Ital. Biol. Sper. 1989, 65(9), 853-9 (Eng).	8
Y	EP 0 316 723 A1 (HOECHST-ROUSSEL) 24 May 1989 (24.05.89), example 5.	8
A	Chemical Abstracts, Vol.109, No.25, 19 December 1988 (Columbus, Ohio, USA), page 847, column 2, abstract No.230870g, SINGH, H. et al.: "Intramolecular chemo-selective heterocyclization of 4-oxothiazolidin-5-yl N-aryldithiocarbamates to fungitoxic 1,3-dithiolo-, 1,3-oxathiolo-, and thiazolothiazoles", Indian J. Chem. Sect. B 1987, 26B(12), 1200-2 (Eng).	7
A	Chemical Abstracts, Vol.112, No.9, 26 February 1990 (Columbus, Ohio, USA), page 785, column 1, abstract No.77014w, ZALESKA, B. et al.: "Substitution reactions of 2-(aroylmethylidene)thiazolidin-4-one derivatives", J. Prakt. Chem. 1989, 331(1), 55-60 (Eng).	7
A	Chemical Abstracts, Vol.84, No.25, 21 June 1976 (Columbus, Ohio, USA), page 566, column 2, abstract No.180117j, ASTIK, R.R. et al.: "Studies on thiazolidinones, Part 1", J. Indian Chem. Soc. 1975, 52(11), 1071-2 (Eng).	8
A	Chemical Abstracts, Vol.85, No.7, 16 August 1976 (Columbus, Ohio, USA), page 521, column 2, abstract No.46484u, ASTIK, R.R. et al.: "Studies on thiazolidinones, Part II", J. Indian Chem. Soc. 1976, 53(3), 272-3 (Eng).	8

PCT/KR 95/00183

Im Recherchenbericht angeführtes Patentedokument Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A1	292305	23-11-88	AT E 78821 DE C0 3873167 DE T2 3873167 DE A0 2781788 DK A 2781788 ES B1 229227 ES T3 2042741 JP A2 7206639 US A 4992245 US A 5106860 JP A2 1279863 JP B4 7030073	15-08-93 00-09-93 00-09-93 00-09-93 00-09-93 00-09-93 00-09-93 00-09-93 00-09-93 00-09-93 00-09-93 00-09-93
EP A1	316723	24-05-89	AT E 81123 AU A1 2569478 AU B2 1622409 CA A1 1311795 DE C0 0007507 DE T2 0007507 DK A0 644567 DK A1 644567 ES B1 2005308 ES T3 2005308 FI A0 8888888 FI A1 8888888 FI A2 8888888 FI C 8888888 HU A2 8888888 HU B 2006709 IE A0 8888888 IE A1 8888888 IE A2 8888888 JP A0 1100000 JP A1 1100000 JP A2 1100000 NO A0 1100000 NO A1 1100000 NO A2 1100000 NO C 1100000 NO E 1100000 NO F 1100000 NO G 1100000 NO H 1100000 NO I 1100000 NO J 1100000 NO K 1100000 NO L 1100000 NO M 1100000 NO N 1100000 NO O 1100000 NO P 1100000 NO Q 1100000 NO R 1100000 NO S 1100000 NO T 1100000 NO U 1100000 NO V 1100000 NO W 1100000 NO X 1100000 NO Y 1100000 NO Z 1100000 NO AA 1100000 NO AB 1100000 NO AC 1100000 NO AD 1100000 NO AE 1100000 NO AF 1100000 NO AG 1100000 NO AH 1100000 NO AI 1100000 NO AJ 1100000 NO AK 1100000 NO AL 1100000 NO AM 1100000 NO AN 1100000 NO AO 1100000 NO AP 1100000 NO AQ 1100000 NO AR 1100000 NO AS 1100000 NO AT 1100000 NO AU 1100000 NO AV 1100000 NO AW 1100000 NO AX 1100000 NO AY 1100000 NO AZ 1100000 NO BA 1100000 NO BB 1100000 NO BC 1100000 NO BD 1100000 NO BE 1100000 NO BF 1100000 NO BG 1100000 NO BH 1100000 NO BI 1100000 NO BJ 1100000 NO BK 1100000 NO BL 1100000 NO BM 1100000 NO BN 1100000 NO BO 1100000 NO BP 1100000 NO BQ 1100000 NO BR 1100000 NO BS 1100000 NO BT 1100000 NO BU 1100000 NO BV 1100000 NO BW 1100000 NO BX 1100000 NO BY 1100000 NO BZ 1100000 NO CA 1100000 NO CB 1100000 NO CC 1100000 NO CD 1100000 NO CE 1100000 NO CF 1100000 NO CG 1100000 NO CH 1100000 NO CI 1100000 NO CJ 1100000 NO CK 1100000 NO CL 1100000 NO CM 1100000 NO CN 1100000 NO CO 1100000 NO CP 1100000 NO CQ 1100000 NO CR 1100000 NO CS 1100000 NO CT 1100000 NO CU 1100000 NO CV 1100000 NO CW 1100000 NO CX 1100000 NO CY 1100000 NO CZ 1100000 NO DA 1100000 NO DB 1100000 NO DC 1100000 NO DD 1100000 NO DE 1100000 NO DF 1100000 NO DG 1100000 NO DH 1100000 NO DI 1100000 NO DJ 1100000 NO DK 1100000 NO DL 1100000 NO DM 1100000 NO DN 1100000 NO DO 1100000 NO DP 1100000 NO DQ 1100000 NO DR 1100000 NO DS 1100000 NO DT 1100000 NO DU 1100000 NO DV 1100000 NO DW 1100000 NO DX 1100000 NO DY 1100000 NO DZ 1100000 NO EA 1100000 NO EB 1100000 NO EC 1100000 NO ED 1100000 NO EE 1100000 NO EF 1100000 NO EG 1100000 NO EH 1100000 NO EI 1100000 NO EJ 1100000 NO EK 1100000 NO EL 1100000 NO EM 1100000 NO EN 1100000 NO EO 1100000 NO EP 1100000 NO EQ 1100000 NO ER 1100000 NO ES 1100000 NO ET 1100000 NO EU 1100000 NO EV 1100000 NO EW 1100000 NO EX 1100000 NO EY 1100000 NO EZ 1100000 NO FA 1100000 NO FB 1100000 NO FC 1100000 NO FD 1100000 NO FE 1100000 NO FF 1100000 NO FG 1100000 NO FH 1100000 NO FI 1100000 NO FJ 1100000 NO FK 1100000 NO FL 1100000 NO FM 1100000 NO FN 1100000 NO FO 1100000 NO FP 1100000 NO FQ 1100000 NO FR 1100000 NO FS 1100000 NO FT 1100000 NO FU 1100000 NO FV 1100000 NO FW 1100000 NO FX 1100000 NO FY 1100000 NO FZ 1100000 NO GA 1100000 NO GB 1100000 NO GC 1100000 NO GD 1100000 NO GE 1100000 NO GF 1100000 NO GG 1100000 NO GH 1100000 NO GI 1100000 NO GJ 1100000 NO GK 1100000 NO GL 1100000 NO GM 1100000 NO GN 1100000 NO GO 1100000 NO GP 1100000 NO GQ 1100000 NO GR 1100000 NO GS 1100000 NO GT 1100000 NO GU 1100000 NO GV 1100000 NO GW 1100000 NO GX 1100000 NO GY 1100000 NO GZ 1100000 NO HA 1100000 NO HB 1100000 NO HC 1100000 NO HD 1100000 NO HE 1100000 NO HF 1100000 NO HG 1100000 NO HH 1100000 NO HI 1100000 NO HJ 1100000 NO HK 1100000 NO HL 1100000 NO HM 1100000 NO HN 1100000 NO HO 1100000 NO HP 1100000 NO HQ 1100000 NO HR 1100000 NO HS 1100000 NO HT 1100000 NO HU 1100000 NO HV 1100000 NO HW 1100000 NO HX 1100000 NO HY 1100000 NO HZ 1100000 NO IA 1100000 NO IB 1100000 NO IC 1100000 NO ID 1100000 NO IE 1100000 NO IF 1100000 NO IG 1100000 NO IH 1100000 NO II 1100000 NO IJ 1100000 NO IK 1100000 NO IL 1100000 NO IM 1100000 NO IN 1100000 NO IO 1100000 NO IP 1100000 NO IQ 1100000 NO IR 1100000 NO IS 1100000 NO IT 1100000 NO IU 1100000 NO IV 1100000 NO IW 1100000 NO IX 1100000 NO IY 1100000 NO IZ 1100000 NO JA 1100000 NO JB 1100000 NO JC 1100000 NO JD 1100000 NO JE 1100000 NO JF 1100000 NO JG 1100000 NO JH 1100000 NO JI 1100000 NO JJ 1100000 NO JK 1100000 NO JL 1100000 NO JM 1100000 NO JN 1100000 NO JO 1100000 NO JP 1100000 NO JQ 1100000 NO JR 1100000 NO JS 1100000 NO JT 1100000 NO JU 1100000 NO JV 1100000 NO JW 1100000 NO JX 1100000 NO JY 1100000 NO JZ 1100000 NO KA 1100000 NO KB 1100000 NO KC 1100000 NO KD 1100000 NO KE 1100000 NO KF 1100000 NO KG 1100000 NO KH 1100000 NO KI 1100000 NO KJ 1100000 NO KK 1100000 NO KL 1100000 NO KM 1100000 NO KN 1100000 NO KO 1100000 NO KP 1100000 NO KQ 1100000 NO KR 1100000 NO KS 1100000 NO KT 1100000 NO KU 1100000 NO KV 1100000 NO KW 1100000 NO KX 1100000 NO KY 1100000 NO KZ 1100000 NO LA 1100000 NO LB 1100000 NO LC 1100000 NO LD 1100000 NO LE 1100000 NO LF 1100000 NO LG 1100000 NO LH 1100000 NO LI 1100000 NO LJ 1100000 NO LK 1100000 NO LL 1100000 NO LM 1100000 NO LN 1100000 NO LO 1100000 NO LP 1100000 NO LQ 1100000 NO LR 1100000 NO LS 1100000 NO LT 1100000 NO LU 1100000 NO LV 1100000 NO LW 1100000 NO LX 1100000 NO LY 1100000 NO LZ 1100000 NO MA 1100000 NO MB 1100000 NO MC 1100000 NO MD 1100000 NO ME 1100000 NO MF 1100000 NO MG 1100000 NO MH 1100000 NO MI 1100000 NO MJ 1100000 NO MK 1100000 NO ML 1100000 NO MM 1100000 NO MN 1100000 NO MO 1100000 NO MP 1100000 NO MQ 1100000 NO MR 1100000 NO MS 1100000 NO MT 1100000 NO MU 1100000 NO MV 1100000 NO MW 1100000 NO MX 1100000 NO MY 1100000 NO MZ 1100000 NO NA 1100000 NO NB 1100000 NO NC 1100000 NO ND 1100000 NO NE 1100000 NO NF 1100000 NO NG 1100000 NO NH 1100000 NO NI 1100000 NO NJ 1100000 NO NK 1100000 NO NL 1100000 NO NM 1100000 NO NN 1100000 NO NO 1100000 NO NP 1100000 NO NQ 1100000 NO NR 1100000 NO NS 1100000 NO NT 1100000 NO NU 1100000 NO NV 1100000 NO NW 1100000 NO NX 1100000 NO NY 1100000 NO NZ 1100000 NO OA 1100000 NO OB 1100000 NO OC 1100000 NO OD 1100000 NO OE 1100000 NO OF 1100000 NO OG 1100000 NO OH 1100000 NO OI 1100000 NO OJ 1100000 NO OK 1100000 NO OL 1100000 NO OM 1100000 NO ON 1100000 NO OO 1100000 NO OP 1100000 NO OQ 1100000 NO OR 1100000 NO OS 1100000 NO OT 1100000 NO OU 1100000 NO OV 1100000 NO OW 1100000 NO OX 1100000 NO OY 1100000 NO OZ 1100000 NO PA 1100000 NO PB 1100000 NO PC 1100000 NO PD 1100000 NO PE 1100000 NO PF 1100000 NO PG 1100000 NO PH 1100000 NO PI 1100000 NO PJ 1100000 NO PK 1100000 NO PL 1100000 NO PM 1100000 NO PN 1100000 NO PO 1100000 NO PP 1100000 NO PQ 1100000 NO PR 1100000 NO PS 1100000 NO PT 1100000 NO PU 1100000 NO PV 1100000 NO PW 1100000 NO PX 1100000 NO PY 1100000 NO PZ 1100000 NO QA 1100000 NO QB 1100000 NO QC 1100000 NO QD 1100000 NO QE 1100000 NO QF 1100000 NO QG 1100000 NO QH 1100000 NO QI 1100000 NO QJ 1100000 NO QK 1100000 NO QL 1100000 NO QM 1100000 NO QN 1100000 NO QO 1100000 NO QP 1100000 NO QQ 1100000 NO QR 1100000 NO QS 1100000 NO QT 1100000 NO QU 1100000 NO QV 1100000 NO QW 1100000 NO QX 1100000 NO QY 1100000 NO QZ 1100000 NO RA 1100000 NO RB 1100000 NO RC 1100000 NO RD 1100000 NO RE 1100000 NO RF 1100000 NO RG 1100000 NO RH 1100000 NO RI 1100000 NO RJ 1100000 NO RK 1100000 NO RL 1100000 NO RM 1100000 NO RN 1100000 NO RO 1100000 NO RP 1100000 NO RQ 1100000 NO RR 1100000 NO RS 1100000 NO RT 1100000 NO RU 1100000 NO RV 1100000 NO RW 1100000 NO RX 1100000 NO RY 1100000 NO RZ 1100000 NO SA 1100000 NO SB 1100000 NO SC 1100000 NO SD 1100000 NO SE 1100000 NO SF 1100000 NO SG 1100000 NO SH 1100000 NO SI 1100000 NO SJ 1100000 NO SK 1100000 NO SL 1100000 NO SM 1100000 NO SN 1100000 NO SO 1100000 NO SP 1100000 NO SQ 1100000 NO SR 1100000 NO SS 1100000 NO ST 1100000 NO SU 1100000 NO SV 1100000 NO SW 1100000 NO SX 1100000 NO SY 1100000 NO SZ 1100000 NO TA 1100000 NO TB 1100000 NO TC 1100000 NO TD 1100000 NO TE 1100000 NO TF 1100000 NO TG 1100000 NO TH 1100000 NO TI 1100000 NO TJ 1100000 NO TK 1100000 NO TL 1100000 NO TM 1100000 NO TN 1100000 NO TO 1100000 NO TP 1100000 NO TQ 1100000 NO TR 1100000 NO TS 1100000 NO TT 1100000 NO TU 1100000 NO TV 1100000 NO TW 1100000 NO TX 1100000 NO TY 1100000 NO TZ 1100000 NO UA 1100000 NO UB 1100000 NO UC 1100000 NO UD 1100000 NO UE 1100000 NO UF 1100000 NO UG 1100000 NO UH 1100000 NO UI 1100000 NO UJ 1100000 NO UK 1100000 NO UL 1100000 NO UM 1100000 NO UN 1100000 NO UO 1100000 NO UP 1100000 NO UQ 1100000 NO UR 1100000 NO US 1100000 NO UT 1100000 NO UU 1100000 NO UV 1100000 NO UW 1100000 NO UX 1100000 NO UY 1100000 NO UZ 1100000 NO VA 1100000 NO VB 1100000 NO VC 1100000 NO VD 1100000 NO VE 1100000 NO VF 1100000 NO VG 1100000 NO VH 1100000 NO VI 1100000 NO VJ 1100000 NO VK 1100000 NO VL 1100000 NO VM 1100000 NO VN 1100000 NO VO 1100000 NO VP 1100000 NO VQ 1100000 NO VR 1100000 NO VS 1100000 NO VT 1100000 NO VU 1100000 NO VV 1100000 NO VW 1100000 NO VX 1100000 NO VY 1100000 NO VZ 1100000 NO WA 1100000 NO WB 1100000 NO WC 1100000 NO WD 1100000 NO WE 1100000 NO WF 1100000 NO WG 1100000 NO WH 1100000 NO WI 1100000 NO WJ 1100000 NO WK 1100000 NO WL 1100000 NO WM 1100000 NO WN 1100000 NO WO 1100000 NO WP 1100000 NO WQ 1100000 NO WR 1100000 NO WS 1100000 NO WT 1100000 NO WU 1100000 NO WV 1100000 NO WW 1100000 NO WX 1100000 NO WY 1100000 NO WZ 1100000 NO XA 1100000 NO XB 1100000 NO XC 1100000 NO XD 1100000 NO XE 1100000 NO XF 1100000 NO XG 1100000 NO XH 1100000 NO XI 1100000 NO XJ 1100000 NO XK 1100000 NO XL 1100000 NO XM 1100000 NO XN 1100000 NO XO 1100000 NO XP 1100000 NO XQ 1100000 NO XR 1100000 NO XS 1100000 NO XT 1100000 NO XU 1100000 NO XV 1100000 NO XW 1100000 NO XX 1100000 NO XY 1100000 NO XZ 1100000 NO YA 1100000 NO YB 1100000 NO YC 1100000 NO YD 1100000 NO YE 1100000 NO YF 1100000 NO YG 1100000 NO YH 1100000 NO YI 1100000 NO YJ 1100000 NO YK 1100000 NO YL 1100000 NO YM 1100000 NO YN 1100000 NO YO 1100000 NO YP 1100000 NO YQ 1100000 NO YR 1100000 NO YS 1100000 NO YT 1100000 NO YU 1100000 NO YV 1100000 NO YW 1100000 NO YX 1100000 NO YY 1100000 NO YZ 1100000 NO ZA 1100000 NO ZB 1100000 NO ZC 1100000 NO ZD 1100000 NO ZE 1100000 NO ZF 1100000 NO ZG 1100000 NO ZH 1100000 NO ZI 1100000 NO ZJ 1100000 NO ZK 1100000 NO ZL 1100000 NO ZM 1100000 NO ZN 1100000 NO ZO 1100000 NO ZP 1100000 NO ZQ 1100000 NO ZR 1100000 NO ZS 1100000 NO ZT 1100000 NO ZU 1100000 NO ZV 1100000 NO ZW 1100000 NO ZX 1100000 NO ZY 1100000 NO ZZ 1100000	